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                                                  INTRODUCTION 
                               Obesity is a huge problem because it leads to so many 
complications such as accelerated atherosclerosis, increased incidence of gallbladder 
disease, type-2 diabetes mellitus, insulin resistance and many carcinomas. There are 
so many causes for obesity but basic root of the obesity is  surplus energy intake in 
foodstuff more than energy expenditure .
(1)
 Obesity results from interaction of 
environmental and genetic factors. Decreased physical activity and reduction in leptin 
receptor sensitivity also play major roles. 
                            There are three important anthropometric dimensions for instance 
weight, height, waist circumference (WC) in the evaluation of obesity degree.
(2,3 )
Body 
Mass Index (BMI)  is derived by dividing the weight by height, BMI = Wt 
(Kilograms) / Ht (meter
2
),which estimates body fat.BMI cannot differentiate between 
fat stack and lean body mass or muscle mass. Excess abdominal fat is measured by 
WC and waist hip ratio (WHR) .
( 3 )
 
                             Obese individuals are at risk of early death from various 
complications. Men with 10 % overweight have 13 percentage greater  hazard of death 
and who are with 20 percentage overweight the risk is increased to 25 percentage.
( 3 )
 
                             Various studies suggested that surfeit weight gain is a key risk 
aspect for hypertension .
(4,5,6,7) 
For every 10 Kg  in body weight there was three mmHg 
climb in systolic bloodpressure and 2.3 mmHg increase in diastolic bloodpressure 
(DBP) explained by  INTERSALT study.
(3) 
WC,BMI,WHR are strongly linked to 
 bloodpressure.
 (5,8)
Various studies suggested that decline in weight leads to 
bloodpressure reduction.
(2,9-12)
 
                         Hypertension is prevalent all over the world and target major organs of 
the body leading to coronary heart disease, cerebrovascular disease, kidney damage 
etc. Approximately 10 – 15 % population is suffered from hypertension. 5–20 % 
ESRD is due to hypertension 
[13] 
.Kidney is a target and cause of hypertension.SBP is 
mainly concerned with kidney damage .
(14 )
NIH detection and follow up programmed 
observed 12 deaths by renal failure among 7825 mild hypertensive patients with DBP 
90 – 104 mmHg which constitutes 0.15 % and 13 deaths by renal failure among 3175 
patients with DBP > 105 mmHg that is 0.42 % deaths are due to renal failure .
(15 )
 
                              Clinically microalbuminuria (a random urine Albumin Creatinine 
Ratio 30 -300 mg / g) or macroalbuminuria (a casual urine ACR more than three 
hundred  mg / g) are the early markers of kidney damage. They are not only indicators 
of renal damage but also markers of progression of kidney damage .
(16, 17-20)
 
                                  Though obesity is a major risk factor for development of 
hypertension and CKD, less attention is paid to link between CKD and Obesity. 
Particularly visceral obesity / central obesity has strong link with CKD through two 
causes: hypertension and diabetes mellitus .
(21)
 
                    Elevated blood pressure affects approximately one billion people that is 
one fourth of adult population worldwide and also major cause of death all over the 
world. Hypertension is one of the major cause of outpatient visit to a physician. So the 
 physicians  have to identify and manage the obese individuals to prevent the 
complications and morbidity. 
                          Reduction in the BP ,will slow down the rate of renal  function 
decline in CKD.
(13)
Reduction in weight of only 5–10 percentage  reduces the 
bloodpressure  in normotensive in addition to obese individuals with elevated BP and 
need for the anti-hypertensive drugs are reduced.
( 9 )
                                    
                         So to avoid all these complications of obesity particularly of central 
obesity, like hypertension and CKD, we must make awareness about physical fitness 
and importance of maintenance of normal body weight through regular physical 
activity and health education about healthy food  habits .     
                          This study was done to investigate the association of BMI and WC 
with hypertensive-CKD (stage I – II). 
                        So by simple health education about healthy diet,physical activity,life 
style modification we can prevent excess body fat accumulation and related 
complications such as hypertension and kidney damage. 
 
 
 
 
 
 
                                            AIMS AND OBJECTIVES 
 
AIM:              
                                    The aim of the present study was to evaluate the association of 
body mass index & waist circumference with hypertensive chronic kidney disease 
(stage I – II).  
OBJECTIVE: 
                                   The purpose of this present study was to investigate whether 
waist circumference (WC) is more linked with GFR (renal function) reduction than 
body mass index ( BMI ) in patients with stage I – II hypertensive chronic kidney 
disease ( CKD ).  
 
 
 
 
 
 
 
 
 
 
 
 
                                              REVIEW OF LITERATURE  
OBESITY : 
                               Obesity is a chronic disorder with an increase in body weight and 
also an excess adipose tissue mass. A recent report by WHO stated that 1.6 billion 
people are overweight (BMI 25 to 30 Kilogram / meter
2
), 400 million people are 
obese ( BMI more than 30 Kg / m
2
 ) worldwide.
(22 )
 
                            There are two major types of adipose tissues namely WAT (White 
adipose tissue) and BAT (Brown adipose tissue). Triglyceride (TG) storage is the 
major function of adipocyte.TG is mainly derived from chylomicrons (from diet) and 
VLDL from liver. Triglyceride is hydrolyzed by hormone sensitive lipase (HSL) to 
free fatty acid (FFA) into the circulation. There is continuous TG  redistribution 
between adipose tissue and other parts of body.
 (2,23 )
 
                         Excess fat is stored in the abdominal region (upper body fat) or in the 
gluteal-femoral region (lower body fat). Intra abdominal fat cells are smaller than fat 
cells in subcutaneous tissue and are more responsive to dietary and hormonal factors 
than those from other areas. Human adipose tissue is richly supplied by alpha and beta 
adrenergic receptors-beta agonists stimulate lipolysis and alpha-2 agonists inhibit 
lipolysis. Lipoprotein lipase (LPL) plays important role in controlling the regional 
distribution of fat.
 
  Factors increase LPL activity : 
1. Insulin 
2. Cortisol. 
 Factors inhibit LPL activity : 
1. Growth hormone   
2. Catecholamines  
3. Tumor Necrotizing Factor (TNF) 
 4. Cytokines  
5. Testosterone. 
Noradrenaline (α2 & β) has more marked response in abdominal fat than gluteal and 
femoral tissues.Gluteal and femoral tissues contain large fat cells. 
Body weight mainly depends on the steadiness between ingestion of calories and their 
utilization. When the caloric intake exceeds caloric utilization that will lead to 
Obesity.There is meal-to-meal regulation of food intake and also body weight is 
maintained at a given set point. Hypothalamus & some parts of brain play key role in 
the control of food intake. Hypothalamus has lateral “feeding center” in the median 
forebrain bundle and a medial “satiety center ” in the ventromedian nucleus.(1,2,3,23) 
Factors that influence appetite :
(1, 2, 13 ,14, 23 ,24)
 
Increase food intake (Orexigenic): 
 AGRP, β-endorphin, Galanin, Ghrelin, GHRH, MCH, Neuropeptide-Y, 
Orexin-A, Orexin-B 
 
 Decrease food intake (Anti-Orexigenic): 
 Bombesin, CART, CCK, CRH, cGRP, Glucagon,GLP-1,2 GRP, Leptin, 
Neurotensin, Oxytocin, Peptide-YY, Somatostatin, α-MSH. 
POMC is cleaved by PC-1 to give alpha MSH and this alpha MSH via MC4R which 
is present in the brain that regulates the intake of food and controls autonomic 
function and finally suppress the appetite and thereby food intake. 
Ghrelin (288) is an aminoacetylated peptide which is secreted by Oxyntic cells of 
fundus of stomach. Concentration of Ghrelin is high before meals and reduced after 
ingestion of meals. 
Ghrelin concentration is inversely related to BMI, while Insulin & leptin are directly 
related to BMI. 
Neurotransmitters of CNS : 
Appetite inhibitors : dopamine, serotonin, GABA 
Appetite stimulators : opiods. 
Endocannabinoid system is implicated in control of central food intake pathway and 
peripheral pathway of food ingestion and energy balance management. 
Cannabinoid receptor 1 – present in cerebral cortex, cerebellum, hippocampus 
Cannabinoid receptor 2 – present in the periphery. 
MCH – is a polypeptide secreted by the fish pituitary and controls their skin colour,in 
mammals m RNA of MCH mainly found in lateral hypothalamus and zona incerta. 
 CART-neuropetide in hypothalamus inhibits food intake. 
   Other factors : 
  Cold weather,empty stomach-increased food intake. 
  Warm weather,distension of gastrointestinal tract-decreased food intake . 
  Obesity is an individual‟s response to the environment or otherwise results from 
interaction of ecological and heritable factors. So many genes are implicated in the 
origin of obesity such as genes controlling adipocyte differentiation, adipocyte 
specific adrenergic receptors, leptin production is controlled by ‟ob‟ gene, ‟db‟ gene 
that controls receptor for leptin and mutation of „ob‟ gene or „db‟ gene causes obesity, 
‟agouti‟ gene which is normally expressed in skin and regulates the melanin 
production, obesity results from mutation of Agouti gene, „fat‟ gene and mutation of 
carboxypeptidase – E results in obesity. 
              Longterm effects of Leptin to elevate the bloodpressure are mostly mediated 
through the SNS which is again mediated by means of hypothalamic pro-
opiomelanocartin. The chief connection between obesity and stimulation of SNS is 
POMC-MC4R pathway. Mutations in POMC or MC4R result in morbid obesity. 
Intact number and sensitivity of beta adrenoreceptors is required for the sympathetic 
signal transmission to the target tissues. β3 Adrenergic receptor is associated with 
increased capacity to gain weight and higher WHR.RNA that encodes for β3 
adrenergic receptor is mainly expressed in intra-abdominal, visceral adipose tissue and 
in BAT but not in subcutaneous adipose tissues in humans.Reduced sympathetic 
 activity results in decreased thermogenesis and subsequent food intake stimulation and 
positive energy balance leading to obesity. 
 
Figure-1.Effects of leptin in the brain.(Berne & Levy Physiology-6
th
 
edition) 
                 Leptin(167aminoacids and16 Kd), ob gene product, is produced by the 
white adipose tissue and also by skeletal muscle, placenta, stomach. It‟s concentration 
in blood is proportional to the amount of fat depots. 
                  Leptin receptors are present in hypothalamus-arcuate, dorsomedial, 
ventromedial and ventral premammilary nuclei and also present in extrahypothalamus 
sites-Nucleus Tractus Solitorius, the Substantia Nigra, theVentral Tegmental area. 
       In obesity the resistance to leptin is the major cause than lack of leptin. Leptin m 
RNA expression is amplified by fasting, hypothalamic damage and decreased by 
feeding. 
 Types of obesity phenotypes :
(2)
 
1. Type one obesity-excess body fat/body mass 
2. Type two obesity-excess subcutaneous truncal and abdominal 
fat(Android) 
3. Type three obesity-high abdominal visceral fat 
4. Type four obesity-excess gluteo femoral fat (gynoid) 
                            Upper body obesity is a more significant cardiovascular hazard 
factor than BMI alone. Upper body fat accumulation is called as „Android‟ type (apple 
shaped / abdominal / visceral / central / intra abdominal) obesity, and the lower body 
fat accumulation is called as „Gynoid‟ type ( generalized  / pear shaped / subcutaneous 
fat ) obesity. 
Central obesity, which is measured by waist circumference (WC) and waist hip 
ratio(WHR), is a better interpreter than BMI to reflect visceral fat. WC was a strong 
predictor for both abdominal and non-abdominal fat. 
 Body Mass Index (BMI) also known as Quetelet Number /  Quetelet Index is derived 
by a formula ,
( 2 ,3 ,23)
 
      BMI ( Kg / m
2
 ) =  Weight in Kilograms / Height in meter
2 
Weight in lbs / Height in inches
2
 × 703 calculates the BMI. 
 Body adiposity classification based on BMI – NIH and WHO :(2,3,13,14,23) 
CATEGORY BMI (Kg/M
2
) OBESITY CLASS 
Under weight      Less than 18.5  
Normal weight    18.5 to  24.9  
Over weight     25.0 to 29.9  
Obesity     30.0 to 34.9 
    35.0 to 39.9 
          I 
          II 
Extreme Obesity       More than or 
equal to 40.0 
          III 
NIH –National Institutes of Health, 
Ethnic specific values for Waist Circumference (WC ) :
(25 )
 
ETHNIC GROUP  WAIST 
CIRCUMFERENCE  
EUROPEANS MALE    ≥ 94 cm(37 inches) 
FEMALE   ≥ 80 cm(31.5 inches) 
SOUTH ASIANS & 
CHINESE 
MALE   ≥ 90 cm(35 inches) 
FEMALE   ≥ 80 cm(31.5 inches) 
JAPANESE MALE   ≥ 85 cm(33.5 inches) 
FEMALE   ≥ 90 cm(35 inches) 
 
BMI provides an estimate body fat .Low level of  BMI thresholds for overweight and 
obesity have been proposed for Asians especially China and India. 
 Assessment of body fat and its distribution: 
 Height & Weight 
 Circumferences 
 Density-Immersion and Plethysmograph 
 Skinfolds 
 Ultrasonogram 
 Heavy water 
 Fat soluble gas 
 Total body electrical conductivity 
 Absorptiometry (DEXA-dual energy x-ray absorptiometry) 
 Computed tomography ( CT ) 
 Magnetic Resonant Imaging ( MRI ) 
 Neutron activation 
Elevated WC and elevated  BMI may precede the onset of morbidity and 
mortality. 
                    For some obesity complications, the regional distribution of fat rather 
than the absolute excess adipose tissue amount appears to be important .Abdominal 
obesity is closely associated with type -2 DM, metabolic syndrome, cardiovascular 
diseases ,kidney damage etc.
(2,313,23)
 
Complications of obesity :
(2, 3, 13, 14 , 22, 23 ,26)
 
Psychosomatic, Osteoarthritis of knee joints an& hip joints,Varicosity of long veins, 
Hiatus hernia,gall bladder stones,Postoperative problems, sprain in back, Accident 
 proneness, Obstructive sleep apnoea, Hypertension, Breathlessness, myocardial 
infarction, Stroke,Type-2 diabetes mellitus, high lipid level in blood, irregular 
menstrual cycle, raised carcinoma risk, Heart failure. 
Excess accumulation of abdominal or visceral adipose tissue is associated with high 
apo-lipoprotein B concentration and reduced plasma HDL level. 
Individuals with excess visceral adipose tissue have high glycemic response to 
glucose challenge in the presence of hyperinsulinemia which indicates insulin 
resistance. 
                           Metabolic changes connected with excess visceral adipose tissue 
(resistance to insulin, glucose intolerance, high level of insulin in blood) are 
considered as risk factors for Non Insulindependent Diabetes Mellitus, metabolic 
syndrome / syndrome X , cardiovascular diseases. 
Insulin resistance is selective (mostly involving metabolism of glucose), tissue 
specific (mainly affects skeletal muscle), and pathway specific (glycogen synthesis is 
mostly affected) in obese hypertensive individuals. And this may modulate the 
hypertension development through various mechanisms such as enhancement of renal 
sodium retention, R-A-A-S activation, sympathetic nervous system activation etc…. 
Obesity treatment :
(2, 3, 22, 23)
 
1. Diet 
2. Exercise 
3. Behavior therapy 
 4. Pharmacotherapy 
5. Surgery 
Pharmacotherapy: 
 Orlistat :  
It is a derivative of lipostatin. It inhibits gastric lipase and pancreatic lipase. So 
that reduces fat absorption and increases triglyceride (TG) excretion in stools. 
Sibutramine : 
It inhibits serotonin (5-HT) and norepinephrine (NE) reuptake at nerve endings. 
Surgical management of obesity : 
1. Surgeries that cause malabsorption : 
 Roux – en – Y gastric bypass surgery 
 Biliopancreatic diversion 
2. Surgeries that cause gastric restriction : 
 Vertical banded gastroplasticity 
 Laproscopic adjustable gastric banding. 
HYPERTENSION : 
                                 Raised blood pressure is one of the major public health issues in 
developed countries.A variety of systems are concerned in the control of arterial blood 
pressure including peripheral and / or central adrenergic system, renal system , 
hormonal and vascular systems. Overweight and obesity are key risk factors for 
 primary / essential hypertension which accounts for 65 – 75 percentage of the hazard 
for essential hypertension.
(5)
Obesity is coupled with Hypertension(HT), Proteins in 
urine, progressive kidney disease. 
Ohnishi et al
(27)
 in their study observed that abdominal obesity was correlated with 
high incidence of hypertension ,Albert et al
(28)
,in their study they induced weight gain 
in dogs and suggested that increase in weight was associated with increase in heart 
rate, BP, cardiac output, plasma volume and fasting insulin concentration. 
                            Various other studies suggested prolonged high fat diet induced 
weight gain,increased the bloodpressure.
(29-31)
Various studies reported BP is 
associated with obesity indices BMI,WC,WHR .
(5,8)
And some other studies showed 
weight gain is a good interpreter of hypertension .
(4,6,7)
 Weight loss is effective in the 
prevention of elevated bloodpressure .
(2,3,13,14,22,32-36) 
Even 5–10 % weight loss reduces 
the bloodpressure in normotensive as well as in hypertensive obese individuals. 
Hypertension is one of the most major reason for renal, cardiovascular and 
cerebrovascular harm. 
 
 
 
 
 
 
        AGE BLOOD PRESSURE(mmHg) 
  AT BIRTH   60 – 75 / 40 
CHILDHOOD  90 – 100 / 50 
PUBERTY  100 – 120 / 60 
 ADULT 120 – 140 / 80 
  ≥ 60 YEARS 140 – 160 / 80 – 90 
 Blood pressure changes with age. 
Classification of blood pressure for adults > 18 yrs old :
(13,25,32-36)
 
(2003 European Society of Hypertension - European Society of Cardiology 
Guidelines for the management of Hypertension) 
CATEGORY SBP (mmHg) DBP (mmHg) 
Optimal    Less than 120      Less than 80 
Normal    Less than 130      Less than 85 
 High normal   130 to  139     85 to  89 
HT-stage 1(mild)   140 to 159     90 to 99 
HT-stage 2 (moderate)   160 to 179    100 to 109 
HT-stage 3 (severe)       More than 180      More than 110 
Isolated systemic HT      More than 140      Less than 90     
 
Two major types of hypertension are : 
1. Essential / idiopathic / primary hypertension –arterial hypertension with no 
definable cause.It accounts for > 90 % of all hypertension cases. 
2. Secondary hypertension – specific structural organ or gene defect is responsible for 
hypertension. It may be due to renal cause, endocrine cause or due to diverse causes.  
Overweight and obesity are the key risk factors for primary/ essential  
hypertension.Visceral fat accumulation-- Insulin resistance and adipokines 
disorders -- increase reabsorption of sodium by the kidney, overactivity of 
 sympathetic nervous system, vascular smooth muscle proliferation, atherosclerosis --
hypertension.(2,3,16,20) 
Augmented sodium reabsorption from the renal tubules and loss of pressure 
natriuresis play significant part in initiating hypertension associated with weight gain. 
Mechanisms involved are: 
1. Increased sympathetic nervous system function 
2. Stimulation of Renin-Angiotensin-Aldosterone-System 
3. Kidney is compressed physicaly by the fat deposition within and around the 
kidney. 
Augmented adrenergic activity plays major role in the development and continuation 
of obesity hypertension in experimental animals and in humans. The renal sympathetic 
nerve mediates most of the longterm effects of sympathetic nervous system (SNS) 
stimulation on blood pressure in obesity. 
   Mediators of SNS activation in obesity: 
 Hyperinsulinemia 
 Angiotensin II 
 ↑ed level of FFA 
 Baroreceptor reflexes impairement 
 Activation of chemoreceptor mediated reflexes coupled with sleep apnoea 
 Cytokines released by the adipocytes(adipokines) are Leptin,TNF-α,IL-6. 
  Hypertension is the major cause for renal, cardiovascular and cerebrovascular 
impairment. 
 Effects of hypertension on various organs .
(13, 14, 33-36)
 
1. On the Heart : 
         Concentric left ventricular hypertrophy which ultimately dilates the cavities and 
leads to heart failure. 
2. Neurological effects : 
       -Hypertensive retinal changes 
       -Occipital headache particularly in the morning is one of the prominent early 
symptom of Hypertension. 
       -Cerebral ischemia 
     - Cerebral haemorrhage 
     - Hypertensive encephalopathy 
3. On the Kidney : 
     Arteriosclerotic lesions of the afferent arteriole and efferent arteriole and the 
glomerular capillary tufts are leading to reduction in GFR and also to tubular 
dysfunction. Approximately 10 % of the deaths by Hypertension results from renal 
failure. 
  In chronic sustained hypertension, stretch activated ionic channels are activated and 
also there is early gene response. Cytokines like TGF-β, growth factors like 
angiotensin-II, EGF, PDGF, CTGF lead to myointimal proliferation and sclerosis 
finally cause vasoconstriction and sclerosis. 
In malignant hypertension, haemodynamic stress causes massive fibrinoid necrosis of 
afferent arteriole and glomeruli, thrombotic microangiopathy, a nephritic urinary 
sediment and acute renal failure. 
HYPERTENSIVE CHRONIC KIDNEY DISEASE : 
  The kidney be a target and also a root of hypertension. When there is increase in the 
arterial pressure, renal arterial pressure enhances the excretion of sodium and water 
until the arterial pressure returns to normal value. Kidneys play major role in long 
term control of blood pressure .
(1,24)
 
Filtering the plasma and removing the substances from the filtrate at variable rates is 
the important function of the kidneys. 
Nephron is the key structural and functional unit of the renal system. Each kidney 
consists of about 80,000 to 1,00,000 nephrons. 
Each nephron contains 1.Glomerulus – is a modified capillary network that delivers an 
ultra filtrate of plasma to Bowman‟s space 2.Tubule – here the filtrate is converted 
into urine. 
The main physiological components of renal functions are: 
1. GFR,                            2. RBF,                              3. Glomerular permeability.     
 The first step in urine formation is glomerular filtration (GF). Plasma is ultrafiltrated 
by glomerulus to get the GF. In normal adult male the glomerular filtration rate (GFR) 
ranges from 90 – 140 ml / min and in female it ranges from 80 – 125 ml / min.(39)Thus 
in 24 hours,glomeruli filtered as much as 180 L of plasma. This GF is devoid of 
cellular elements and devoid of protein .
(39)
 
 
 
 
 
 
 
 
 
 
 
 
Figure -2. Basic renal processes .(Sherwood Human Physiolgy-4
th
 edition.)  
  GFR = Kf [( PGC - PT ) – ( πGC – πT ) ] 
Kf =Glomerular ultrafiltration co-efficient 
 PGC=Glomerular hydrostatic pressures 
PT =Mean tubular hydrostatic pressure 
    πGC=Glomerular capillary plasma osmotic pressure 
    πT =Tubular filtrate osmotic pressure 
GFR depends on Glomerular blood flow,Ultra filtration pressure, the area and the 
composition of the filtration barrier. 
The net filtration pressure (PUF ) is 15 mmHg at the afferent arteriolar end and falls to 
zero at the efferent end of glomerular capillary.
(1)
 
Factors affecting the GFR :
(1,16,17,20,24,39,40)
 
 Alteration in  blood flow to the kidney (RBF) 
 Alteration  in Glomerular capillary hydrostatic pressure 
 Systemic hypertension 
 Afferent and efferent arteriolar narrowing 
 Plasma proteins concentration change (dehydration, hypoproteinemia) 
 Edema of kidney inside tight renal capsule 
 Changes in Bowman‟s capsule hydrostatic pressure 
 Ureteral obstruction 
 Any alteration in filtration co-efficient 
 Changes in Glomerular capillary permeability 
 Changes in Effective filtration surface area.   
 The GFR can be measured by various methods :
(1, 24, 40)
 
 Inulin clearance test  
C INULIN (or GFR) = Uin V / Pin = 35 × 0.9/0.25  
                              =126 ml / min. 
 Creatinine clearance test 
C = UV / P 
The plasma creatinine concentration is inversely proportional to GFR. 
 Urea clearance test  
Urea clearance is less than the glomerular filtration and also protein diet 
influences GFR. So it is not as sensitive as the previous one to assess the renal 
function. 
Kf is altered by mesangial cells.mesangial cell contraction producing a decrease in Kf   
Factors causing mesangial contraction and relaxation: 
Relaxation : 
Atrial natriuretic peptide (ANP), Dopamine, Prostaglandin E2 , c AMP 
 
Contraction : 
Endothelins, A-II, Vasopressin, Norepinephrine, Platelet activating factor (PAF), 
PDGF, Tx - A2, Prostaglandin F2, Leukotreins-C4 and D4, Histamine 
  
 PHYSICAL DETERMINANTS PHYSIOLOGIC / PATHOLOGIC 
CAUSES 
↓ Kf    - ↓ GFR Renal diseases, diabetes mellitus , high 
bloodpressure 
↑ PBC  - ↓ GFR Urinary tract obstruction (eg.nephrolithiasis) 
↑ πGC - ↓ GFR ↓ bloodflow to kidney , ↑ plasma proteins 
↓ PGC - ↓ GFR Reduced arterial pressure 
↓ RE  - ↓  PGC Decreased Angiotensin – II 
↑ RA  - ↓  PGC Increased Sympathetic activity , 
vasoconstrictor hormones 
( norepinephrine,endothelins) 
 
HORMONES / AUTOCOIDS EFFECT ON GFR 
Norepinephrine           Reduced 
Epinephrine           Decreased 
Endothelin           Reduced 
Angiotensin – II           ↔ 
Endothelin derived Nitric Oxide           Elevated 
Prostaglandin           Raised 
 
                          Intrinsic feedback mechanism in kidneys normally keeps the renal 
blood flow (RBF) and GFR relatively constant. The relative constancy of GFR and 
RBF is called Autoregulation.GFR and RBF are also substantially controlled by SNS, 
catecholamines, angiotensin-II, prostaglandins, nitric oxide, endothelin, natriuretic 
peptdides, bradykinin and adenosine. 
Renal blood vessels which includes afferent and efferent arterioles are richly supplied 
by sympathetic nerves. Strong activation of sympathetic nerves causes constriction of 
renal arterioles leading to decrease in the RBF and GFR. 
Macula densa feedback mechanism for autoregulation of PGC and GFR consists of 
afferent arteriolar feedback mechanism and efferent arteriolar feedback mechanism. 
This feedback mechanism depends on JGA (Juxta Glomerular Apparatus). 
    JGA includes :  
 1. Macula Densa cells –specialized epithelial cells of distal tubule of kidney. 
2. JG cells – present in the afferent and efferent arterioles. 
3. Mesangial cells 
Elevated blood pressure causes failure of autoregulation of afferent arteriole 
bloodflow, this causes glomerular hypertension which leads to hyperfiltration, 
hypertrophy and focal segmental glomerulosclerosis which again causes loss of 
autoregulation. 
(16,20,24,41)
 
                          
Figure-3.Structure of JGA.(Guyton and Hall-Textbook of Medical 
Physiology-12
th
edition). 
     
Figure-4.Viscious circle that can occur with primary kidney damage.              
( Guyton and Hall-Textbook of Medical Physiology-12
th
editon ). 
 The risk associated with hypertension is graded and continuous. The risk for renal 
injury is strongly related to systolic blood pressure (SBP) more than diastolic blood 
pressure(DBP).    
 Among chronic renal disease patients in the Modification of Diet in Renal Disease     
(MDRD) study, greater baseline MAP (mean arterial pressure) measurements were 
independently prognostic of a greater rate of GFR reduction.
(43)
The magnitude of 
increased risk of ESRD is associated with the blood pressure level, so even mild 
elevations of blood pressure lower than the threshold level for diagnosis of 
hypertension were associated with increased ESRD risk. 
Another study said that although elevated blood pressure is an independent risk of 
ESRD systemic hypertension is associated with increased risk of ESRD .
(43)
 
The degree of arcuate and interlobular arterial thickening is related to the severity of 
hypertension. There are two patterns of hypertensive glomerulosclerosis .
(37, 38)
 
1. Ischaemic obsolescence – collapsed glomerular tufts surrounded by intercapsular 
fibrosis filling the Bowman‟s space. 
2.Glomerular solidification – global glomerulosclerosis seen.Loss of glomerular tuft 
cells and collagen and matrix material deposition in the Bowman‟s 
space,fragmentation of Bowman‟s capsule and the solidified tuft merges with the 
surrounding ineterstitial fibrous tissues.                                                    Obesity 
induced kidney damage is due to many factors like hormones, pro-inflammatory 
 molecules produced by adipocytes, high level of mineralocorticoids, reduced 
adiponectin levels.
(14,16,20,41)
                                     
  Chronic Kidney Disease (CKD) is a pathologic process with multiple etiologies, 
resulting in the inexorable attrition of number of and function of nephron and 
frequently leading to ESRD. 
NKF-KD provides CKD definition as:
(45) 
1 .Kidney injury for more than three months, as defined by structural or functional 
renal abnormalities, with or without reduction in GFR, manifested either : 
 abnormal pathological lesions or 
 markers of  renal injury, with abnormalities in the blood or urine 
composition or abnormal imaging test. 
2. GFR less than 60 ml / min / 1.73 m2 for more than three months, with or 
without kidney damage. 
Incidence of CKD, progression of CKD and the incidence of ESRD are increased with 
elevated systolic blood pressure. 
Albuminuria is one of the oldest and most sensitive marker of the kidney 
damage.
(16,17,20,44)
 
Protienuria can also be measured by various methods. 
 Radio immuno Assay-using double antibody technique; 
 Immunoturbidimetric method, 
 Laser nephelometer;  
  ELISA ; 
 High performance liquid chromatography. 
Prevalence of CKD (% of the population affected)
[26]
 : 
 
CKD 
STAGES 
                                  AGE  ( YEARS ) 
Under 65 (% ) 65 to 74 ( % )  75 to  84 ( % )     More than 
85 ( % ) 
         III     1.4      15.4      29.4        30.9 
         IV     0.04      0.4      1.3        2.4 
         V     0.03      0.1      0.2        0.1 
       Total      1.5      15.9      30.9        33.4 
        
Categorization of CKD into 5 stages is mainly to manage the patients according to the 
stages. 
Risk factors of CKD:
(13,14,16,17,20,42)
 
-Inherited renal disease in family, Elevated bloodpressure, Diabetes 
Mellitus, Autoimmune disease, Older age, Past episode of ARF 
The following table shows the incidence of risk factors causing CKD : 
The percentage of hypertension causing CKD is 27.4 %, the elevated blood pressure is 
the second common cause of CKD, next to diabetes mellitus. 
 
                      PRIMARY CAUSE INCIDENCE (%) 
Diabetes mellitus    44.8 
Hypertension,Large vessel disease   27.4 
Glomerulonephrtis   7.7 
Interstital nephritis    3.4 
Cystic,Heriditary,Congenital disorders    3.1 
Neoplasms,Tumours   2.4 
Secondary glomerulonephritis,Vasculitis    2.2 
Cause unknown    7.5 
 
Functions of kidney and renal function impairment in CKD patients:
(17)
 
KIDNEY FUNCTION CONSEQUENCES OF DYSFUNCTION 
Maintainance of concentration 
& body electrolyte and fluid 
volume control 
Reduced plasma sodium level, low plasma 
potassium, Hypocalcemia, high phosphate in 
blood 
Controls blood pressure Hypertension, diseases of Cardiovascular system  
Mediator of Endocrine function  Anaemia,Hypertension,Bone disease,Low vit-D 
activation,Prolonged half-lives of peptide 
hormones 
Removal of Waste products   Anorexia,Nausea,deposition of oxalates and 
phosphates in Soft tissue,Neurologic dysfunction, 
muscle protein loss. 
 Classification and staging of Chronic Kidney Disease(CKD) by the National 
Kidney Foundation: 
(16,17,20,41)
 
     STAGE        DESCRIPTION GFR(ml/min/1.73m²) 
        1 Kidney damage with normal or 
increased GFR 
          ≥90 
        2 Kidney damage with mild reduction 
in  GFR 
        60 to 89 
        3 Kidney damage with moderate  
decrease in GFR 
        30 to 59 
        4 Kidney damage with severe  ↓ GFR         15 to  29 
        5 Renal  failure        Less than 15 or dialysis 
Kidney damage  -  pathological abnormalities  /  abnormality in blood or urine 
investigations or imaging studies. 
                                                  Stage 3  to 5 CKD patients are vulnerable to fluid 
accumulation, volume overload, high plasma potassium, hyponatremia and azotemia. 
Once GFR has decreased below a critical level, CKD tends to develop to ESRD 
regardless of initial injury. 
Hypertension especially systolic hypertension is a powerful promoter of renal injury. 
Bloodpressure control reduces the threat of CKD progression. 
Risk factors for progression of kidney disease: 
(46)
 
 Proteinuria more than  1.5 g / 24 hour or urine protein to creatinine ratio more 
than 1 g / g. 
  Elevated bloodpressure 
 Type of underlying renal pathology 
 African American race 
 Males 
 Obesity and dyslipidemia 
 Smoking 
 High protein diet 
 Phosphate retention 
 Metabolic acidosis 
Complications of Chronic Kidney Disease(CKD): 
(13,14,42)
 
All organs are affected, but important complications are  ; 
Anaemia, Loss of energy, Decreasing appetite, nutritional status disorder, 
Abnormalities in calcium and phosphorous metabolism accompanied by metabolic 
bone disease, Abnormalities in sodium, water, K 
+ 
and acid-base homeostasis. 
Management of CKD : 
Stage 1-2 : Diet adjustment,management of BP and glycemia, R-A-A-S inhibitors 
Stage 3 : management of anaemia, renal bone disease , dietary modification 
Stage 4 : 3 + haemodialysis(if needed) and End Stage Renal Disease management 
Stage 5 : 4 + dialysis + CKD complication management. 
So according to stages CKD is managed. 
        By assessing the clinical presentation we can presume the etiology: 
(14)
 
        CAUSE  CLINICAL PRESENTATION 
Diabetic kidney disease  Diabetes,Proteinuria,Retinopathy 
Hypertension Elevated blood pressure,normal urine 
analysis,family history 
Non diabetic glomerular 
disease 
Nephritic or nephritic presentation 
Cystic renal disease Renal tract symptoms, abnormal sediments in 
urine,abnormal radiologic imaging tests. 
Tubulointerstitial disease Urinary tract infection and reflux,longterm 
medication,abnormal urine analysis,abnormal 
urinary imaging. 
 
Laboratory investigations in renal insufficiency: 
(47)
 
URINE : 
Simple urine analysis is important to diagnose renal damage esp. chronic kidney 
disease. 
 Dipstix examination 
 Urine examination (RBC, RBC casts, WBC, WBC casts, Tubular cells,  
Granular casts, Oval fat bodies, Fatty casts or Free fat) 
 Quantitative analysis of twenty four hour urine volume 
 BLOOD : 
 Complete blood count (CBC ) 
 Autoanalyser profile (blood urea, serum creatinine, bicarbonate, calcium, 
phosphate, alkaline phosphatase, glucose, Hb A1C ) 
 Serological tests ( HBsAg, HBsAb, HCAb, HIV, ANF, ANCA, Anti-GBM, 
Anti-ds-DNA ) 
 RADIOLOGICAL INVESTIGATIONS : 
 X-ray chest (CXR) 
 Renal ultrasonogram 
 Renal tract plain radiograph 
 IV urogram, CT scan, MRI, renogram, angiogram. 
ECHOCARDIOGRAM  
ECG 
RENAL BIOPSY 
Comprehensive strategy for renoprotection in CKD patients : 
(32 )
 
1. ACE Inhibitors – ARB 
2. Antihypertensive management 
3. Nutritional protein restriction 
4. Strict glycemic control 
5. Cessation of smoking 
6. Lipid lowering treatment 
 Protein composition of normal urine : 
(46)
 
In healthy adults, minimal amount of glomerular and tubular origin proteins are 
excreted, averaging 80 mg / 24 hours. 
            PROTEIN EXCRETION(mg/day)  
Plasma protein 
1. Albumin 
2. Ig G 
3. Ig A 
4. Ig M 
5. Light chains 
 Ƙ 
 ƛ 
     6.β microglobulin 
     7.other plasma proteins 
 
12.0 
3 
1 
0.3 
 
2.3 
1.4 
0.12 
20.0 
 Total plasma protein 40.0 
Non plasma protein 
1. Tamm-Horsfall protein 
2. Other non renal derived protein 
 
40.0 
 
< 1 
 Total non plasma protein 40.0 
       
Total urinary protein = 80 ± 24 (SD) mg / day. 
 Microalbuminuria: 
(44-47)
 
  The main markers used to assess renal function damage are GFR, microalbuminuria 
and macroalbuminuria. The chief determinants of microalbuminuia are central or 
abdominal obesity and systolic blood pressure.  Microalbuminuria is defined as 30 – 
300 mg albumin / 24 hr urine. Albuminuria is defined as (more than 300mg/24 hrs) a 
persistent excretion rate exceeding that of microalbuminuria. Microalbuminuria and 
macroalbuminuria were independent ESRD predictors after 10.3 years.   
 Most plentiful  plasma protein is albumin. Urinary excretion of albumin is determined 
by the combined effects of glomerular filtration and processing by renal tubules. 
Albumin concentration in glomerular ultrafiltration is between 1 and 50 μg/ ml, this 
corresponds to albumin filtration load between 170 mg and 9 g per 24 hours, in 
healthy adults. 
(16)
 
Reduced GFR and albuminuria in combination were important predictors of ESRD. 
Microalbuminuria is the earliest sign of nephropathy before it manifests as overt 
proteinuria. 
Microalbuminuria is classified as: 
1. Albumin Excretion Ratio (AER) : 20 to 200 μg / minute or 30 to 300 
mg / day. 
2. Albumin / Creatinine Ratio ( ACR ) : 2.5 to  25 mg / mmol. 
3. Albumin / Creatinine : 30 to 300 mg / day. 
4. Albumin Concentration (in early morning urine) : 30 to 300 mg / L. 
 Microalbuminuria denotes high probability of damage of the renal glomerular 
filtration capacity and is of great diagnostic relevance. 
 In Diabetes Mellitus – for eary diagnosis of nephropathy. 
 In Hypertension – ESRD indicator. 
 MA is also associated with cardiovascular diseases. 
Interfering factors of microalbuminuria estimation : 
 Sternous exercise 
 High protein diet 
 High salt intake 
 Haematuria 
 Menses 
Microalbuminuria is associated with : 
 Diabetic Mellitus with early diabetic nephropathy 
 Hypertensive cardiovascular diseases 
 Generalized vascular diseases 
 Pre-eclampsia 
Microalbuminuria also occurs in : 
 Ischemia    
 Trauma 
 Thermal injury  
 Surgery 
  Pancreatitis 
 Inflammatory bowel disease (IBD) 
GFR estimation equations (e GFR ) : 
(16,20,41-47)
 
The GFR level can be estimated by using formula which includes serum creatinine 
level and some variables for instance age, gender, body size and race. 
Modification of Diet in Renal Disease ( MDRD ) equation : 
                              GFR (ml/min) = 170 × [ serum creatinine level(mg/dl) ]
-0.999 
 × 
[Age (years) ]
-0.176
 × ( 0.762,if female ) × (1.180 if African American race) × ( BUN 
mg/dl )
-0.170
×(Albumin )
0.318
. 
       Since the publication of NKF-CKD guidelines, the widespread method used to 
measure the renal function is the simplified four variable Modification of Diet in 
Renal Disease ( MDRD ) equation : 
GFR (ml/min/1.73m
2
) = 186  × [Serum Creatinine ]
-1.154
 × [Age in years]
-0.203
 × [0.742 
if patient is female gender ] × [1.212 if the patient is black race ]. 
CKD-EPI. Equation : 
                                  GFR (ml/min/1.73 m
2
) = 141 × min. (serum creatinine / K,
1
)
α
 × 
max. (serum creatinine / K,
1
)
-1.209
 × 0.993
 Age
 × 1.018 (if female) × 1.159 (if black). 
 K = 0.7 for female and 0.9 for male ; 
α =  -0.329 for female and -0.411 for male. 
 
 Cockcroft- Gauti Formula : 
Creatinine clearance (ml/min) = [ ( 140 – Age in years ) × ( Body weight in Kg ) ] / ( 
Serum creatinine (mg/dl) × 72 ) ; 
 If the patient is female , this value is multiplied by 0.85. 
Other formulas to measure GFR 
[48]
 : 
Scwartz Formula : 
GFR = 0.55 × Height (in cm ) / Serum creatinine ( mg / dl ) 
Counahan – Barrett formula : 
GFR = 40 × Height ( in cm ) / serum creatinine ( μmol / L ) 
Modified Schwartz formula : 
GFR = 39.1 [ Height ( meter ) / Serum creatinine level( mg / dl ) ]
 0.516 
× [ 1.8 / cystatin 
( mg / dl )]
 0.294 
 × [ 30 / Blood Urea Nitrogen ( mg / dl ) ] 
0.169
 [ 1.099 ] 
male
 [ Height (in 
meters ) / .4 ]
 0.188
 
Creatinine: 
(25,44,47)
 
Serum creatinine is widely used to estimate GFR. Creatinine (MW 113 Da) is the 
cyclic anhydride of creatine which is produced by phosphocreatine decomposition. 
Creatinine is synthesized from methionine, glycine and arginine. Creatinine is 
excreted by the kidney. The rate of excretion of creatinine is constant relatively from 
day to day. Plasma creatinine and renal creatinine clearance are diagnostic indicators 
of renal function. Narrow range of serum creatinine level is mainly maintained by 
 glomerular filtration. The serum creatinine level initially changes slightly with 
decrease in the GFR. So minimal changes in the serum creatinine level will evoke 
major changes in the GFR level. But when the GFR decreases to < 40ml / min / 1.73 
m
2
, huge change in serum creatinine level correspond to little GFR changes occur. 
Serum creatinine is estimated by two methods: 
1. Chemical method, 
2. Enzymatic method. 
The Jaffe reaction (chemical method) : Creatinine reacts with picrate in alkaline 
medium which yields an orange-red complex.   
Factors that affect serum creatinine level are :  
 changes in the muscle mass, 
 nutritional status, 
 physical activity  
 Metabolism of creatinine in gut. 
 Drugs like diuretics, chloralhydrate,  marijuana, guanethedine, 
furosemide, chloremphenical, sulfonamides. 
Increased Creatinine level seen in the conditions such as : 
 renal dysfunction, 
 diminished renal blood flow ( Shock , Dehydration ), 
 congestive heart failure, 
 diabetes Mellitus (DM) 
  Acromegaly, Gigantism 
 Hypothyroidism 
Decreased Creatinine level seen in : 
 Muscular Dystrophy 
 Polymyositis and neurogenic atrophy 
 Hyperthyroidism 
 Anaemia 
 Inflammatory muscular diseases 
 Advanced renal diseases and renal stenosis 
 leukemia 
Urea: 
(25,41-47)
 
 Urea is a byproduct of the protein and aminoacid metabolism.Urea is mainly 
(90%) excreted by the kidney. 
Factors that affect blood urea concentration are: 
1. High protein diet, 
2. Elevated protein catabolism, 
3. Following GIT haemorrhage increased reabsorption of blood protein, 
4. Cortisol treatment, 
5. Dehydration, 
6. Decreased renal blood flow. 
    Blood urea level can be estimated by two methods: 
1. Chemical method, 
2. Enzymatic method. 
Enzymatic method is of four types: 
1. Equilibrium photometric, 
2. Kinetic photometric, 
3. Conductiometry, 
4. Dry chemistry system. 
In enzymatic method, urea is first hydrolyzed by using urease to get ammonia .And 
this ammonia is quantified. 
Other studies related to this present study : 
                           Hyunju oh et al : 
(49 )
 In their study “Waist Circumference(WC), not 
BMI ,is associated with renal function decline in Korean population : Hallym Aging 
Study ”,454 persons with GFR > 60 ml/min/1.73 m2  participated and followed for 6 
years and their renal function decline was assessed. Their result showed that 
abdominal obesity and not Body Mass Index was correlated with faster renal function 
drop and so it may be a better interpreter than BMI for renal function decline. 
                            Janssen et al: 
(50 )
 studied about “ WC and not BMI explains obesity 
related health risk ”.It was a six years study included 14,924 persons aged more than 
17years.WC,height,weight, serum cholesterol, Triglycerides, lipoprotein,glucose were 
 estimated.In their study they observed BMI together with WC does not predict an 
increased obesity related health problem better than WC alone. 
                           In their study “Obesity ,anthropometric measures and CKD 
complications ”, Navaneethan et al (51) included 2,853 adult CKD patients and WC, 
HC, BMI, Haemoglobin, total cholesterol, serum albumin and bicarbonate level ,PTH 
level,e GFR were measured .The result was ,Obese based on both WC and BMI had 
higher odds of CKD complications than non-Obese participants and those with BMI 
less than 30 Kg / m
2
  with heigh WC was not associated with an  with high WC was 
not associated with any CKD complications. 
                “ Relationship between Abdominal Obesity (AO) and Microalbuminuria 
(MA) in elderly ” was studied by Mohmoud  AH and Taha HM . (52 )This cross-
sectional study  included 200 elderly persons with the age group of > 60 years and 
Height,Weight,BMI,WC,HC,WHR were measured.Blood pressure was assessed and 
urine ACR was done.Statistical analysis was done by using independent t-test and 
paired-t-test.Conclusion was AO is strongly associated with Microalbuminuria in 
Egyptian elderly. 
                    Ohnishi et al : 
(27)In their study about “ Incidence of hypertension in 
individuals with abdominal obesity in a rural Japanese population : The Tanno and 
Sobetsu study ”,396 individuals aged ≥ 30 years were participated .WC,BMI,Systolic 
blood pressure (SBP),Diastolic blood pressure (DBP),fasting plasma glucose,total 
cholesterol,TG,HDL were measured for all the participants.The unpaired t-test and  ᵪ2 
were used for statistical analysis.Group -1 included individuals with Abdominal 
 Obesity(AO) and Group-2 included non-AO .The result showed increased incidence 
of hypertension in group-1.  
                              Seok Huikang et al : 
( 53 )
 studied “ Association of visceral fat area 
(VFA) with CKD and Metabolic syndrome (MS) risk in the general 
population:Analysis using multi-frequency bioimpedence ”.In this study,22,480 
patients were grouped into low , middle , high tertiles based on their 
VFA.WHR,BMI,SBP,DBP,FPG,T.CH.,TG,AST,ALT and uric acid levels were 
increased as the VFA tertile increased and HDL level ,e GFR decreased as the VFA 
tertile increased. 
                    “prevalence of Renal Insufficiency (RI) in individuals with hypertension 
and obesity / overweight : the FATH study ” conducted by Pablo Gomez et al ( 54 )in 
5,585 pateints with hypertension and GFR ≥ 25 Kg / m2.FPG,HbA1c ,total 
cholesterol,LDL,HDL,TG,serum creatinine were analysed.e GFR was estimated by 
using  MDRD and C – G equation.They observed that the occurrence of renal injury 
was greater in patients with abdominal obesity. 
                      Kosaku Nitta 
( 55 )
 in his review article,he emphasised that „metabolic 
syndrome which includes visceral obesity, dyslipidemia, hypertension, impaired 
insulin sensitivity was an important risk factor CKD and cardiovascular diseases. 
                      Ribstein et al : 
( 56 )
 studied “ Combined renal effects of overweight and 
hypertension ” .In this comparative study,in hypertensive patients obesity causes a 
greater filtration fraction and more microalbuminuria, that showed that the increase in 
weight intensifies hypertensive renal damage. 
                       Hall et al 
(21)
 in their review article about Obesity,hypertension,and 
chronic renal disease,concluded that obesity induces a cascade of changes within the 
kidney and neurohormonal alteration that lead to impairment in renal pressure 
natriuresis,high sodium reabsorption,elevated bloodpressure and renal damage.  
                     Yi-Jing Sheen and Wayne Huey-Herng Shew 
(57) 
in their review 
article,mentioned about the risk factors for type-4 cardio-renal syndrome which 
included diabetes mellitus, hypertension, low HDL cholesterol, physical inactivity, 
non-traditional risk factors like albuminuria, oxidative stress, increased sympathetic 
tone. 
                   Ana Karina et al 
( 58 )
 conducted a cross-sectional study and observed that 
BMI and WC were not associated with e GFR based on serum creatinine and cystatin-
C, only Visceral Fat Area was associated with decrease in e GFR. 
                      Kambham et al 
(59) 
in an article suggested the link incidence of obesity 
and risk of obesity-related glomerulopathy. 
                    Chi Yuan Hsu et al 
(60) 
in their large Cohart study about BMI and risk for 
ESRD, they observed a graded strong relationship between the risk for ESRD and 
high BMI. 
                   “  Obesity induced hypertension in the dogs ” was conducted by Albert et 
al . 
(28 )
In this study nine adult dogs were fed with beef fat for five weeks to increase 
weight and suggested increase weight was associated with increase in heart rate, BP, 
cardiac output, plasma volume, fasting insulin concentration. 
                     Pinto Sietsma SJ et al 
(19)
 in their study they observed microalbuminuria 
( MA ) was associated with abnormal renal function in non-diabetic individuals. 
                   In their study about central obesity and hypertension Scaglione R.et al 
(61)
, 
they found that both in normotensive and hypertensive subjects ,those with central 
obesity had elevated urine albumin excretion rate than with peripheral obesity. 
                   Chang Y et al 
(62 )
in 2006 conducted a study on abdominal obesity, SBP, 
MA in normotensive and euglycemic Korean men and found that SBP was an 
independent predictor of microalbuminuria. 
                  Association of WC and BMI with all cause mortality in CKD was studied 
by Krammer H et all . 
(63)
In that study higher mortality was associated with higher 
WC and not associated with high BMI. 
            
                  
 
 
 
 
 
 
 
                           MATERIALS AND METHODS : 
                 This case-control study was conducted in the Department of Physiology, 
Thanjavur Medical College Hospital, Thanjavur. 
 Forty normal healthy subjects and forty Hypertensive Chronic Kidney Disease ( HT-
CKD, Stage I – II ) patients  were recruited from Thanjavur Medical College Hospital, 
Thanjavur, in the  age group of  between > 18 years and < 70 years , study was 
conducted between June 2015 and May 2016.  
                   Before starting our study, we obtained ethical committee approval and 
clearance from the college. Informed written consent was obtained from all the 
subjects who were participating in this study. The purpose of this study was explained 
clearly in their regional language. The history of the subjects was obtained and noted 
in a separate pro-forma. 
Inclusion Criteria : 
 Chronic kidney disease (Stage 1-2 ) 
 Hypertension 
 Non-diabetic 
 Free from cardiovascular complications 
Exclusion Criteria : 
 History of any malignancy 
 History of or presence of inflammation 
  Presence of major cardiovascular event like CVA,myocardial infarction,acute 
IHD during last three months prior to the study 
 Diabetes mellitus 
 Heart failure 
 Heriditary renal disease 
  Detailed clinical history was evaluated and Physical examination was done for every 
participants. 
Anthropometric measures like height (in meters), weight (in kilograms) ,waist 
circumference (in centimeters) and hip circumference (in centimeters)  were 
measured. 
Waist Circumference (in centimeters) : 
(64)
 
Waist circumference was measured at the midpoint between the lower margin of least 
palpable rib and the top of iliac crest at the end of normal expiration in standing 
position with arms at the sides and feet positioned closed together .The optimal waist 
circumference for males < 90 cm and for females < 80 cm for South-Asian ethnic 
groups. WC is an important measurement of central obesity. 
 Hip circumference (in centimeters ) : 
(64)
 
 Hip circumference (HC) was measured around the widest portion of the buttocks with 
tape parallel to the floor. 
 
 
 BMI ( in Kg / m
2
 ) : 
 BMI was calculated by dividing weight in Kg by height in meter square,Waist hip 
ratio (WHR) was calculated by dividing waist circumference by hip circumference  
and WHR is expressed in centimeters.The normal BMI range is 5 – 24.9 Kg / m2. 
Bloodpressure (BP in mmHg) measurement: 
(33)
 
BP is a dynamic physiological function and it varies with each heart beat. For 
measurement of blood pressure(BP) appropriate size cuff is important. Appropriate 
size cuff was selected based on mid arm circumference (MAC) of the participants. 
Based on MAC and bladder dimension in American Heart Association Guidelines 
the following cuff sizes are recommended : 
 Small adult MAC range 22 – 27.5 cm, width 12 cm, length 22 cm ; 
Adult MAC range 30 – 37.5 cm, width 16 cm, length 30 cm ;   
Large adult range 38 – 47.5 cm, width 16 cm, length 38 cm ; 
The blood pressure was measured in a quiet and relaxed setting after five minutes of 
rest with feet relaxed and flat on the floor .The participants were seated with their 
back against chair and the arm wearing cuff was supported at the elbow and was kept 
at the level of heart .The cuff was tied 2.5 cm above the cubital fossa. The blood 
pressure was measured by palpatory method followed by using mercury 
sphygmomanometer. The cuff was deflated at a rate of 2 – 4 mmHg/sec in the 
auscultatory method, appearance of Korotkoff sound (phase I ) was considered as 
 systolic blood pressure (SBP) and disappearance of Korotkoff sound (phase IV) was 
considered as diastolic blood pressure (DBP).  
European Society of Cardiology Guidelines for management of Hypertension and 
Joint National Committee Guidelines for Detection, Evaluation and Management 
of Hypertension defined hypertension as SBP ≥ 140 mmHg and DBP ≥ 90 mmHg. 
Serum creatinine estimation ( in mg / dl ) : 
(44)
 
For serum creatinine estimation, 5 ml of venous blood was taken  in the red –topped 
(serum separator ) tube from the medial cubital vein  in the anti-cubital fossa of  the 
participants under sterile condition. Serum creatinine was measured by using Jaffe’s 
kinetic method by using auto analyzer. The normal range of serum creatinine for 
males 0.6 – 1.2 mg/dl, and for females 0.4 – 1.0mg/dl. 
Blood urea estimation ( in mg / dl ): 
(44,65)
 
 For the blood urea estimation, to get 5 ml of venous blood,  a sterile needle was 
gently guided in the anti-cubital vein of the participants after cleaning the skin of 
puncture site and was estimated by enzymatic ( kinetic ) method by using 
autoanalyzer . 
The normal range is 15 – 45 mg / dl. 
24-hours urine Albumin Excretion Rate (AER in mg/24 hrs ):
 (44,48,65)
 
 Then to assess renal function 24-hours urine was collected for the estimation of 
Albumin Excretion Rate (AER).The importance of the test was explained clearly to 
the participants. Heavy physical work and high protein diet intake were restricted on 
 the previous day and the day of urine collection. Normal fluids and food intake was 
allowed. Fluids was not forced to avoid of very diluted urine. The participants were 
asked to empty the bladder completely on awakening and discard the first urine 
specimen and all the urine voided over the next 24 hours was collected in a large 
sterile container which contained a preservative (thymol) to reduce bacterial action or 
chemical decomposition. This 24 hours urine collection was delivered to the 
laboratory without delay. Normal AER is < 30 mg . 
Microalbuminuria is defined as 30 – 300 mg albumin excretion / 24 hours urine. 
Macroalbuminuria is defined as urine albumin excretion > 300 mg / day. 
e GFR (ml/min/1.73m
2
) : 
GFR was estimated by using MDRD formula, 
(16, 20)
 
    e GFR (ml/min/1.73m
2
) = 186  × [Serum Creatinine level ]
-1.154
 × [Age ]
-0.203
 × 
[0.742 if patient is female ] × [1.212 if the patient is black ]. 
The normal average GFR is 125 ml / min. Normal  glomerular filtration rate (GFR) 
ranges from 90 – 140 ml / min for adult male and ranges from 80 – 125 ml / min in 
females. 
(39)
 
Thus the anthropometric and renal function parameters were measured to compare the 
effect of BMI and waist circumference on renal function decline in hypertensive 
chronic kidney disease. 
 
 
 The following instruments were used in this study : 
1. Auto-Analyzer( BECKMAN COUTLER,AU – 480 ) 
2. Urine analyzer (COBOS 6000-HITACHI ) 
3. LIQUIXX Urea ( BUN ) Kit for blood urea estimation 
4. LIQUIXX Creatinine Kit for serum creatinine estimation 
5. Weighing machine (KRUPS ) 
6. Sphygmomanometer ( DIAMOND ) 
7. Stethoscope ( MICROTONE ) 
8. Sterile container for urine collection and preservative (Thymol ) 
9. Test tubes for blood collection 
10. Inch tape 
11. Miscellaneous things like spirit, cotton, syringes, needles.   
                 
 Figure–5.Auto Analyser for urea and creatinine.( BECKMAN COUTLER,AU – 
480 ). 
            
      Figure – 6.Auto Analyser for 24-hrs urine AER.( COBOS 6000-HITACHI ). 
 
Figure-7. LIQUIXX Urea ( BUN ) Kit for blood urea estimation 
                  LIQUIXX Creatinine Kit for serum creatinine estimation 
  
Figure-8. Weighing machine, inch tape, sphygmomanometer, stethoscope. 
 
Figure–9.Other materials used in this study (Red topped test tubes, syringes, 
cotton, container for urine collection and its preservative.)   
 
In this study, thymol was used as preservative for 24 hours urine collection to prevent 
bacterial growth which may affect the expected result. 
             
 
 Other urine preservatives :
(65)
 
PRESERVATIVES CONCENTRATION / VOLUME 
HCl 6mol /L;30 ml/24 hr collection 
Acetic acid 50%;25 ml / 24 hr collection 
Na2CO3 5g / 24 hr collection  
HNO3 6 mol/ L; 15ml/ 24 hr collection  
Baric acid 10 g/ 24 hr collection 
Toluene 30 ml / 24 hr collection 
Thymol 10 % in isopropanol;10 ml /24 hr 
collection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                RESULTS 
  In this case-control study which was conducted in Thanjavur Medical 
College,control group consisted  fourty healthy adults ;and the study group included 
fourty hypertensive chronic kidney disease ( stage I – II )  patients.In the study 
group,Group 1- included patients with normal waist circumference and normal 
BMI,Group 2-included patients with high waist circumference and normal BMI,Group 
3-included patients with normal waist circumference and high BMI. 
                    Statistical analysis was done by using the Statistical Package for Social 
Sciences ( SPSS ) X version.The results were analyzed by using student „t‟ test and 
ANOVA study.Datas are expressed in mean with standard deviation.Correlation of 
BMI and WC,WHR with various renal function by using Pearson‟s Correlation test. 
P < 0.05 was considered as statistically significant. 
  Descriptive analysis was done for all the parameters and are tabulated in Table-1. 
                       The parameters are age, height, weight, systolic blood pressure, 
diastolic blood pressure, BMI, waist circumference, WHR, urea, creatinine, AER and 
e GFR. 
                                                         
 
 
 
 
                                                 TABLE - 1 
                                        DESCRIPTIVE STATISTICS 
CLINICAL PARAMETERS OF CONTROL AND STUDY GROUPS 
  
Parameters 
Study HT-CKD (n=40) Control  (n=40) Total subjects (n=80) 
Mi
n. 
Max
. 
Mea
n 
S.D 
Mi
n. 
Ma
x. 
Mean S.D 
Mi
n. 
Ma
x. 
Mean S.D 
Age ( yrs ) 38 53 
43.8
8 
3.568 38 52 46.28 3.796 38 53 45.08 3.854 
SBP             
( mmHg) 
130 150 
141.
90 
4.199 
10
0 
130 
117.0
5 
7.089 
10
0 
150 
129.4
7 
13.77
9 
DBP   
(mmHg) 
86 96 
89.9
5 
2.660 70 84 78.95 3.328 70 96 84.45 6.292 
Height(m ) 1.50 1.68 
1.59
03 
.0382
0 
1.5
1 
1.72 
1.610
3 
.0512
7 
1.5
0 
1.72 
1.600
3 
.0460
3 
Weight(Kg) 52 73 
59.9
5 
5.383 50 64 55.83 2.978 50 73 57.89 4.794 
BMI(Kg/m
2
) 
19.1
0 
28.7
0 
23.7
60 
2.305
49 
2.3
0 
24.4
0 
21.13
57 
3.368
47 
2.3
0 
28.7
0 
22.44
79 
3.157
36 
WC(cm) 76 110 
88.9
5 
8.750 76 86 82.10 2.362 76 110 85.53 7.241 
HC(cm) 82 110 
96.5
8 
5.509 76 98 85.02 4.764 76 110 90.80 7.743 
WHR .83 1.08 
.923
0 
.0750
5 
.83 1.03 .9388 
.0482
1 
.83 1.08 .9309 
.0631
7 
Urea(mg/dl) 41 62 
51.1
0 
6.172 12 32 21.32 4.323 12 62 36.21 
15.88
9 
Creatinine 
(mg/dl) 
.86 1.22 
1.06
20 
.1165
4 
.40 .73 .5823 
.0911
3 
.40 1.22 .8221 
.2628
2 
eGFR(ml/mi
n/1.73 m
2
) 
60 85 
69.0
5 
8.779 
10
3 
217 
139.5
7 
27.81
7 
60 217 
104.3
1 
40.97
8 
AER(mg/24 
hrs) 
35 190 
76.0
5 
41.12
1 
3 14 6.42 3.38 3 190 41.23 45.47 
 
 
 
 The result shown in Table-1 are as follows : 
The mean age of control group was 46.28 ± 3.79 yrs 
The mean age of study group was 43.88 ± 3.56 yrs 
The mean height of control group was 1.61 ± 0.05 m 
The mean height of study group was  1.59 ± 0.03 m 
The mean weight of control group was 55.822 ± 2.97 Kg  
The mean weight of study group was 59.95 ± 5.38 Kg 
                                      The systolic and diastolic blood pressure of the control and the 
study groups-1,2,3 are expressed in mean ± standard  deviation in Table – 2. 
The mean SBP of control group was  117.05 ± 7.08 mmHg 
The mean SBP of study group-1 was  141.57 ± 5.33 mmHg 
The mean SBP of study group-2 was  142.71 ± 3.64 mmHg 
The mean SBP of study group-3 was  141.33 ± 3.44 mmHg 
The mean DBP of control group was  78.95 ± 3.32 mmHg  
The mean DBP of study  group-1 was  90.14 ± 2.98 mmHg 
The mean DBP of study  group-2 was  90.57 ± 2.87 mmHg 
The mean DBP of study group-3 was  89.0 ± 1.80  mmHg 
                                                        
                                                TABLE – 2 
SYSTOLIC AND DIASTOLIC BLOOD PRESSURE OF CONTROL AND 
STUDY GROUPS 
PARICIPANTS         SBP (mmHg )      DBP ( mmHg ) 
 
    CONTROL 
     GROUP 
N 40 40 
Mean 117.05 78.95 
SD 7.08 3.32 
       
     STUDY 
   GROUP-1 
N 14 14 
Mean 141.57 90.14 
SD 5.33 2.98 
 
     STUDY 
   GROUP-2    
N 14 14 
Mean 142.71 90.57 
SD 3.64 2.87 
 
      STUDY 
   GROUP-3 
N 12 12 
Mean 141.33 89.00 
SD 3.44 1.80 
 
                                             
 
 
 
                                                            TABLE -3 
        DESCRIPTIVE ANALYSIS OF SBP & DBP  IN STUDY AND CONTROL   
GROUPS 
Bloodpressure Mean S.D 
    T DF Statistical 
inference  
SBP(mmHg)      
Study group 
(N=40) 
141.90 4.199 
19.075 78 
.000<0.05 
Significant  Control 
group(N=40) 
117.05 7.089 
DBP(mmHg)      
Study group 
(N=40) 
89.95 2.660 
16.331 78 
.000<0.05 
Significant  Control 
group(N=40) 
78.95 3.328 
 
                                 
Figure-11.Comparison of SBP,DBP between control & study groups. 
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 Table-3 and Figure-11 show the comparison of SBP and DBP in the study and the 
control groups. Mean SBP and the mean DBP between study and control groups were 
statistically more significant. 
Analysis of  SBP and DBP between study group-1,group-2,group-3 by using ANOVA 
study are shown in Table 4.  The mean difference of SBP and  DBP between study 
group-1,group-2,group-3 were not statistically significant.   
                                                      TABLE -4 
ANALYSIS SBP & DBP BETWEEN STUDY GROUPS BY ANNOVA STUDY 
BLOODPRESSURE Mean SD SS Df MS F 
Statistical 
Inference 
SBP(mmHg)        
Between Groups   14.648 2 7.324 
.403 
.671>0.05 
Not 
Significant  
Group-1(N=14) 141.57 5.331    
Group-2(N=14) 142.71  3.646     
Group-3(N=12) 141.33   3.447      
Within Groups   672.952 37 18.188 
DBP(mmHg)        
Between Groups   16.757 2 8.379 
1.196 
.314>0.05 
Not 
Significant  
Group-1(N=14) 90.14  2.983    
Group-2(N=14) 90.57 2.875    
Group-3(N=12) 89.00 1.809      
Within Groups   259.143 37 7.004 
                                                              TABLE -5 
          DESCRIPTIVE ANALYSIS OF WEIGHT ,BMI,WC,HC IN STUDY AND 
CONTROL GROUPS 
Parameters Mean S.D T Df Statistical inference  
WEIGHT(Kg)      
Study group (N=40) 59.95 5.383 
4.241 78 
.000<0.05 
Significant  Control group(N=40) 55.82 2.978 
                BMI(Kg/m
2
)      
Study group (N=40) 23.7600 2.30549 
4.066 78 
.000<0.05 
Significant  Control group(N=40) 21.1358 3.36847 
WC(cm)      
Study group (N=40) 88.95 8.750 
4.780 78 
.000<0.05 
Significant  Control group(N=40) 82.10 2.362 
HC(cm)      
Study group (N=40) 96.58 5.509 
10.030 78 
.000<0.05 
Significant Control group(N=40) 85.03 4.764 
 
The comparison of weight(Kg),waist circumference(cm),hip circumference(cm),waist 
hip ratio are shown in Table-5 and Figure- 12  
 
  
   Figure-12.Comparison of Weight,WC,HC,BMI between control and study 
groups. 
The  mean weight of the control group was 55.82 ± 2.978 Kg. The  mean weight of 
the study group was 59.95 ± 5.383 Kg 
The mean BMI of the control group was  21.13 ± 3.36 Kg/m
2
The mean BMI of the 
study group was  23.76 ± 2.30 Kg/m
2
 
The mean WC of the control group was  82.10 ± 2.36 cm.The mean WC of the study 
group was  88.95 ± 8.75 cm 
The mean HC of the control group was  85.03 ± 4.76 cm. The mean HC of the study 
group was  96.58 ± 5.50 cm 
                          The mean weight, BMI, WC, HC between the control and the study 
groups were statistically significant.                                       
55.82
82.1 85.03
21.13
59.95
88.95
96.58
23.76
0
20
40
60
80
100
120
WEIGHT(Kg) WC(cm) HC(cm) BMI(Kg/m²)
CONTROL GROUP STUDY GROUP
                                                                 TABLE – 6 
                     BMI,WC,HC,WHR  OF CONTROL AND STUDY GROUPS 
 
PARICIPANTS 
   
BMI(Kg/m
2
) 
 
WC(cm) 
 
HC(cm) 
 
WHR 
 
    CONTROL 
     GROUP 
N 40 40 40 40 
Mean 21.13 82.10 85.02 0.93 
SD 3.36 2.36 4.76 0.04 
       
     STUDY 
   GROUP-1 
N 14 14 14 14 
Mean 21.84 81.93 93.36 0.87 
SD 1.18 2.37 5.19 0.03 
 
     STUDY 
   GROUP-2    
N 14 14 14 14 
Mean 23.11 100.0 100.86 1.00 
SD 0.97 3.86 4.64 0.05 
 
      STUDY 
   GROUP-3 
N 12 12 12 12 
Mean 26.75 84.25 95.33 0.88 
SD 1.06 2.22 3.47 0.02 
 
Mean ± Standard deviation of obesity parameters ( Weight, BMI, WC, HC,WHR ) of 
the study group (Group-1, Group-2, Group-3 ) and the control group are represented 
in Table -6 
The mean BMI of study group-3 was 26.75 ± 1.05 Kg / m². The mean WC of study 
group-2 was 100 ± 3.86 cm. 
                                                         TABLE -7 
   ANALYSIS OF WEIGHT, BMI, WC, HC, WHR BETWEEN STUDY 
GROUPS BY ANOVA STUDY 
Parameters 
Mean  S.D SS Df MS F Statistical 
inference  
WEIGHT(Kg)        
Between 
Groups 
  845.215 2 422.67 
54.869 
.000<0.05 
Significant  
Group-1(N=14) 56.29 2.091    
Group-2(N=14) 57.64 1.216    
Group-3(N=12) 66.92 4.358    
Within Groups   284.976 37 7.702 
BMI(Kg/m
2
)        
Between 
Groups 
  164.572 2 82.287 
71.267 
.000<0.05 
Significant  
Group-1(N=14) 21.8429 1.17912    
Group-2(N=14) 23.1143 .97417    
Group-3(N=12) 26.7500 1.05787    
Within Groups   42.721 37 1.155 
WC(cm)        
Between 
Groups 
  2664.441 2 1332.220 
153.455 
.000<0.05 
Significant  
Group-1(N=14) 81.93 2.369    
Group-2(N=14) 100.00 3.863    
Group-3(N=12) 84.25 2.221    
Within Groups   321.215 37 8.681 
HC(cm)        
Between 
Groups 
  420.180 2 210.090 
10.180 
.000<0.05 
Significant  
Group-1(N=14) 93.36 5.198    
Group-2(N=14) 100.86 4.639    
Group-3(N=12) 95.33 3.473    
Within Groups   763.595 37 20.638 
WHR        
Between 
Groups 
  .150 2 .075 
39.799 
.000<0.05 
Significant  
Group-1(N=14) .8771 .03750    
Group-2(N=14) 1.0064 .05930    
Group-3(N=12) .8792 .02275    
Within Groups   .070 37 .002 
 
 Analysis of weight, body mass index, waist circumference, hip circumference, waist 
hip ratio of study groups by ANOVA study is tabulated in Table-7. 
The mean difference of these values (Weight, BMI, WC, HC, WHR) were statistically 
significant between and within the study groups. 
 
 
Figure-13. Comparison of BMI, WC, HC between control and Group-1, Group-2 
and Group-3 of study groups. 
The mean BMI of study group-3 (26.75 ± 1.06 Kg/m
2
) was more than that of study 
group-2 (23.11 ± 0.97 Kg/m
2
) and study group-1 (21.84 ± 1.18 Kg/m
2
) which was 
statistically significant P < 0.05 . 
The WC of study group-2 (100.0 ± 3.86 cm) was statistically significantly (P < 0.05) 
high than that of study group-1 (81.93 ± 2.37 cm) and study group-3 (84.25 ± 2.22 
cm) . 
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                        Table-8 and the Figures- 14-16 show the comparison of blood 
urea,serum creatinine levels,e GFR and AER of the study and control groups.                     
                                                       TABLE -8 
DESCRIPTIVE ANALYSIS OF UREA,CREATININE, e GFR,AER IN STUDY 
AND CONTROL GROUPS 
Parameters Mean S.D 
T Df Statistical 
inference  
Urea( mg/dl)      
Study group (N=40) 51.10 6.172 
24.991 78 
.000<0.05 
Significant  Control group(N=40) 21.33 4.323 
Creat(mg/dl)      
Study group (N=40) 1.0620 .11654 
20.510 78 
.000<0.05 
Significant  Control group(N=40) .5823 .09113 
e GFR(ml/min/1.73m
2
)      
Study group (N=40) 69.05 8.779 
-
15.291 
78 
.000<0.05 
Significant  Control group(N=40) 139.57 27.817 
AER(mg/24 hrs)      
Study group (N=40) 76.05 41.121 
9.496 78 
.000<0.05 
Significant  Control group(N=40) 6.42 3.38 
 
The mean blood urea of the control group was  21.33 ± 4.32 mg/dl 
The mean blood urea of the study group was  51.10 ± 6.17 mg/dl 
The mean serum creatinine of the control group was  0 .58 ± .09 mg/dl.The mean 
serum creatinine of the study group was   1.06 ± 0.12 mg/dl 
 The mean blood urea and the mean serum creatinine between study and control groups 
were statistically more significant. 
 
Figure-14 &15.Comparison of urea between control & study group and of 
creatinine between the same two groups respectively. 
 
 
 
 
 
 
 
 
                 Figure-16. Comparison of e GFR & AER between control and study 
groups 
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 The mean e GFR of the control group was  139.57 ± 27.81 ml/min/1.73m
2 
The mean e GFR of the study group was   69.05 ± 8.78  ml/min/1.73m
2 
The mean AER of the control group was  6.42 ± 3.38  mg/24 hrs 
The mean AER of the study group was  76.05 ± 41.12  mg/24 hrs 
The mean e GFR and the mean AER between study and control groups were 
statistically more significant. 
 
Analysis of blood urea and serum creatinine levels between and within the study 
groups were done and are shown in Table-9 and between study and control groups are 
tabulated and  are shown in Table - 10.The mean values of all groups are plotted in 
figures 17 & 18. 
 
 
 
 
 
                                              
 
 
                                                         TABLE -9 
 ANALYSIS OF UREA, CREATININE BETWEEN STUDY GROUPS BY 
ANOVA STUDY 
Parameters 
Mean  S.D SS Df MS F Statistical 
inference  
UREA(mg/dl)        
Between 
Groups 
  398.163 2 199.081 
6.791 
.003<0.05 
Significant  
Group-1(N=14) 47.79 5.236    
Group-2(N=14) 50.57 5.840    
Group-3(N=12) 55.58 5.107    
Within Groups   1086.673 37 29.370 
CREAT(mg/dl)        
Between 
Groups 
  .387 2 .193 
50.086 
.000<0.05 
Significant  
Group-1(N=14) .9350 .08309    
Group-2(N=14) 1.1664 .04217    
Group-3(N=12) 1.0883 .05219    
Within Groups   .143 37 .004 
 
The mean serum creatinine of study group-1 was  0.93 ± 0.08 mg/dl 
The mean serum creatinine of study group-2 was  1.16 ± 0.04 mg/dl 
The mean serum creatinine of study group-3 was  1.08 ± 0.05 mg/dl. 
The mean serum creatinine of Group-2 ( 1.16 ± 0.04mg/dl ) was higher than  Group-3 
( 1.08 ± 0.05mg/dl) and Group-1(0.93 ± 0.08mg/dl).     
The mean blood urea level of Group-3 (55.58 ± 5.11 mg/dl ) was higher than  Group-1 
(47.79 ± 5.24 mg/dl) and Group-2(50.57 ± 5.84 mg/dl).     
 
  
Figure – 17.Mean S.Creatinine levels in study groups and control group. 
 
 
Figure – 18.Mean blood Urea levels in study groups and control group. 
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                                                            TABLE – 10 
                     UREA AND CREATININE OF CONTROL AND STUDY GROUPS                       
 
   PARICIPANTS 
 
UREA(mg/dl) 
CREAT(mg/dl) 
 
    CONTROL 
     GROUP 
N 40 40 
Mean 21.33 0.58 
SD 4.32 0.09 
       
     STUDY 
   GROUP-1 
N 14 14 
Mean 47.79 0.93 
SD 5.23 0.08 
 
     STUDY 
   GROUP-2    
N 14 14 
Mean 50.57 1.16 
SD 5.84 0.04 
 
      STUDY 
   GROUP-3 
N 12 12 
Mean 55.58 1.08 
SD 5.10 0.05 
 
                       Analysis of e GFR and AER between and within the study and the 
control groups were done and is shown in Table-11 and 12. The mean values are 
depicted in figures 19  -  21. 
                                                     
                                              TABLE – 11 
             eGFR AND AER OF CONTROL AND STUDY GROUPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
 
 
PARICIPANTS eGFR(ml/min/1.73m
2
) AER(mg/24 
hrs) 
 
    
CONTROL 
     GROUP 
N 40 40 
Mean 139.57 6.42 
SD 27.81 3.38 
       
     STUDY 
   GROUP-1 
N 14 14 
Mean 78.71 45.0 
SD 6.95 6.61 
 
     STUDY 
   GROUP-2    
N 14 14 
Mean 61.36 115.29 
SD 1.59 42.77 
 
      STUDY      
GROUP-3 
N 12 12 
Mean 66.75 66.50 
SD 3.621 22.25 
                                                        TABLE -12 
 ANALYSIS OF e GFR, AER BETWEEN STUDY GROUPS BY ANOVA 
STUDY 
Parameters 
Mean  S.D SS Df MS F Statistical 
inference  
eGFR(ml/min/1.73m
2
)        
Between Groups   2199.579 2 1099.789 
50.466 
.000<0.05 
Significant  
Group-1(N=14) 78.71 6.955    
Group-2(N=14) 61.36 1.598    
Group-3(N=12) 66.75 3.621    
Within Groups   806.321 37 21.792 
AER(mg/24 hrs)        
Between Groups   36144.043 2 18072.021 
22.437 
.000<0.05 
Significant  
Group-1(N=14) 45.00 6.610    
Group-2(N=14) 115.29 42.776    
Group-3(N=12) 66.50 22.253    
Within Groups   29801.857 37 805.456 
 
The mean e GFR of the control group was  139.57 ± 27.81 ml/min/1.73m
2
 
                           The mean e GFR of study Group-1(78.71 ± 6.95 ml/min/1.73m
2
) was 
higher than study Group-2(61.36 ± 1.59ml/min/1.73m
2
) and study Group-3 (66.75 ± 
3.62ml/min/1.73m
2
) which was statistically significant P < 0.05 .  
The mean AER of the control group was  6.42 ± 3.38  mg/24 hrs. 
                                  The mean AER of study Group-2(115.29 ± 42.77 mg/24 hrs ) 
was statistically significantly( P < 0.05) higher than study Group-3(66.50 ± 22.25 
mg/24 hrs) and  study Group-1(45.0 ± 6.61 mg/24 hrs).    
                                                      
 
Figure – 19.Mean e GFR  levels in study groups and control group. 
 
Figure – 20.Mean AER levels in study groups and control group. 
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 The mean e GFR of the study group-3 which had normal WC and high BMI was 
higher (statistically significant P < 0.05 ) than that of study group-2 which had high 
WC and normal BMI  and  the mean e AER of the study group-2 which had high WC 
and normal BMI was higher (statistically significant P < 0.05 ) than that of study 
group-3 which had normal WC and high BMI 
The mean AER of the study group-1was  45.0 ± 6.61 mg/24 hrs 
The mean AER of the study group-2 was 115.29  ±  42.77 mg/24 hrs  
The mean AER of the study group-3 was 66.50  ±  22.25 mg/24 hrs  
The mean AER of the study group-2 was higher (statistically significant P < 0.05 ) 
than that of study group-1 and study   group-2.  
The mean AER of the study group-3 which had normal WC and high BMI was 
lower(statistically significant P < 0.05) than that of study group-2 which had high WC 
and normal BMI  . 
 
  
Figure-21. Comparison of e GFR & AER between control and study group-1, 
study group-2, study group-3. 
 
   At the same time renal function decline was more in study group-2 than study 
group-3.. 
Microalbuminuria which is defined as AER 30 – 300 mg / 24 hrs urine ,is an 
important and most sensitive marker of renal damage .High AER in study group-2 in 
this study indicates that renal damage was more in the study group with high WC that 
is renal function decline was more with central obesity than with high BMI.  
  The mean difference of these renal function parameter values ( blood urea, serum 
creatinine, e GFR,AER ) were statistically significant between and within the study 
group. 
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 Table-13 & 14 and figures 22 & 23 show the correlation of BMI with renal function 
decline of the study group with stage 1-2 HT-CKD.Statistically significant correlation 
between BMI with e GFR decline (negative correlation) was observed in the study 
group and also no significant correlation between BMI with serum creatinine level 
elevation and elevated AER level.There is positive correlation between BMI and 
blood Urea level. 
                                               TABLE-13 
                                          STUDY GROUP (N=40) 
                                  Correlations of BMI with renal parameters 
BMI( Kg/m
2
 ) 
Correlation value  Statistical inference  
CREAT( mg/dl ) .301 p>0.05 Not Significant  
e GFR(ml/min/1.73m
2  
) 
  
-.320(*) 
p<0.05 Significant  
AER( mg/24 hrs ) 
  
-.002 
p>0.05 Not Significant  
* Correlation is significant at the 0.05 level 
                                                          TABLE-14 
                                         STUDY GROUP (N=40) 
                     Correlations of BMI with blood pressure & blood urea 
BMI( Kg/m
2
 ) Correlation value  Statistical inference  
SBP( mmHg ) -.139 p>0.05 Not Significant  
DBP( mmHg ) -.273 p>0.05 Not Significant  
UREA( mg/dl ) .356(*) p<0.05 Significant  
* Correlation is significant at the 0.05 level 
                                
 
                Figure – 22. Negative correlation of BMI with e GFR 
 
 
 
Figure – 23.Positive correlation of BMI with blood urea level 
0
10
20
30
40
50
60
70
80
90
0 5 10 15 20 25 30 35
e GFR(ml/min/1.73 m²)
e GFR(ml/min/1.73 m²)
0
10
20
30
40
50
60
70
0 5 10 15 20 25 30 35
Blood Urea(mg/dl)
Blood Urea(mg/dl)
                                                   TABLE-15 
STUDY GROUP (N=40) 
Correlations of WC with renal parameters 
WC( cm ) 
Correlation value  Statistical inference  
CREAT( mg/dl ) .675(**) p<0.01 Significant  
e GFR(  ml/min/1.73m
2
 )
     
 
   
-.689(**) 
p<0.01 Significant  
AER ( mg/24 hrs ) 
   
.685(**) 
p<0.01 Significant  
** Correlation is significant at the 0.01 level 
 
 
                                                     TABLE-16 
                                      STUDY GROUP (N=40) 
                        Correlations of  WC with blood pressure & blood urea 
 
WC( cm ) Correlation value  Statistical inference  
SBP(mmHg ) -.060 p>0.05 Not Significant  
DBP( mmHg ) .176 p>0.05 Not Significant  
UREA( mg/dl ) -.073 p>0.05 Not Significant  
 
                                            
  
Figure – 24. Negative correlation of waist circumference with e GFR 
 
 
 
 
     Figure – 25. Positive correlation of waist circumference with AER 
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Figure – 26. Positive correlation of waist circumference with serum creatinine 
level 
 
Table-15 & 16 and figures 24 – 26 show the correlation of WC with renal function 
decline of the study group consisted of stage 1-2 HT-CKD patients.Statistically 
significant negative correlation between WC with e GFR, positive correlation between 
WC  and serum creatinine level and positive correlation between WC and AER were 
observed in the study group in this present study. 
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                                                   TABLE-17 
STUDY GROUP (N=40) 
    Correlations of WHR with renal parameters 
WHR 
Correlation value  Statistical inference  
CREAT( mg/dl ) .507(**) p<0.01 Significant  
e GFR ( ml/min/1.73m
2 
) 
  
-.535(**) 
  p<0.01 Significant  
AER( mg/24 hrs ) 
.601(**) 
p<0.01 Significant  
** Correlation is significant at the 0.01 level 
 
                                                      TABLE-18 
STUDY GROUP (N=40) 
Correlations of WHR  with blood pressure & blood Urea level 
WHR Correlation value  Statistical inference  
SBP( mmHg ) .230 p>0.05 Not Significant  
DBP( mmHg ) .152 p>0.05 Not Significant  
UREA( mg/dl ) .101 p>0.05 Not Significant  
 
 
 
  
              Figure – 27. Negative correlation of waist hip ratio with e GFR 
 
 
 
         Figure – 28. Positive correlation of waist hip ratio with AER 
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Figure – 29. Positive correlation of waist hip ratio with serum creatinine level 
 
There are significant negative  correlation between WHR and e GFR level , positive 
correlation between WHR and serum creatinine level and also positive correlation 
between WHR and AER level were observed in the study group and are represented in 
Tables-17 & 18 and Figures 27 – 29. 
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                                                    DISCUSSION 
 Obesity is a risk factor for cardiovascular diseases, hypertension, diabetes mellitus 
etc...But awareness of association between obesity and kidney damage is 
less.Prevalence of obesity is rapidly increasing now a days. Obesity is a chronic 
disorder that should be treated in a long term basis. 
           The main function of adipose tissue is the storage of triglyceride. Triglyceride 
is continuously redistributed in the adipose tissue and other parts of the body. 
Regional distribution of adipose tissue is important than the absolute amount of excess 
accumulation of adipose tissue. 
          Excess body fat accumulation accounts for 65 % - 75 % of essential 
hypertension. 
In obesity, there is increased sympathetic nervous system activity, R-A-A-S 
activation, renal compression by accumulation of fat around the kidney. Increased 
adrenergic activity plays major role in the development of hypertension in obesity. 
Many factors are released by adipocytes such as,hormones-
adiponectin,resistin,leptin,cytokines-TNF-α,IL-6,substrates-FFA,glycerol,enzymes-
aromatase,complement factors-Factor-D,adipsin and also other Substances like PAI-1, 
angiotensinogen, RBP-4.These substances damage the peripheral tissues. 
 Obesity  ↑ RPF  Glomerular hyperfiltration. 
 Elevated systemic BP  transmitted to glomerulus  Glomerular 
hypertension  ↑ glomerular damage. 
  So both Hypertension and Obesity cause glomerular hyperfiltration which, over time 
lead to kidney damage.Obesity may directly cause a specific form of glomerulopathy 
(focal and segmental glomerulosclerosis). 
Hallen et al 
( 18 ) 
suggested ,elevated mean arterial pressure was an independent 
predictor of kidney function decline. 
   Klag et al 
( 43 )
 suggested elevated systolic bloodpressure was associated with 
elevated ESRD risk. 
In our study, elevated level of both SBP and DBP were associated with kindey 
damage .  
               Weight loss is associated with decrease in bloodpressure.Haynes et al 
( 66 ) 
and Jones et al 
( 6 ) 
 in their study they had proved it. 
CKD is defined as progressive and irreversible renal function loss. There are five 
stages of CKD based on e GFR values. 
CKD Stage I – II : e GFR ≥ 60 ml / min/1.73 m2; UAC ≥ 30 – 299 mg / g                     
( microalbuminuria ) and ≥ 300 mg / g ( macroalbuminuria ). 
CKD Stage III – IV : e GFR 15 – 59 ml / min / 1.73 m2 . 
  Microalbuminuria not only indicates renal damage but is also an independent and 
well recognized marker of CKD progression.   
  Visceral / abdominal / central obesity is closely associated with renal damage when 
compared to high BMI. 
 Janssen et al 
( 50 )
suggested that WC not the BMI was associated with obesity related 
health risk ,and in their  study Janssen et al observed that WC was a better predictor 
of both abdominal and non-abdominal fat. 
In our study, we observed that both high BMI and increased WC ( visceral / central 
obesity ) were associated with reduced renal function ( reduced e GFR, elevated serum 
creatinine level,high AER,Blood Urea) ; but in high waist circumference more decline 
in kidney function was observed than other groups . 
Hyunju Oh et al 
( 49 ) 
,Noori et al 
( 67 ) 
,Elsayed et al 
( 68 )
  in their study suggested that 
abdominal obesity was a better predictor and a major risk factor for renal function 
decline. 
C Y Hsu et al 
( 61 ) 
 , Vupputuri et al 
( 69 )
 observed that BMI was associated with 
CKD in their studies. 
Some other studies 
( 67,70,71 )
 reported BMI and Abdominal obesity both are risk factors 
for CKD. 
 Mahmoud et al 
( 52 )
 found that Abdominal obesity was strongly associated with 
microalbuminuria which is a better marker of renal damage. 
In our study, there was strong statistically significant correlation of WC and WHR 
which are the indicators of central or abdominal obesity, with renal function reduction 
in stage I & II HT-CKD patients. And the correlation of BMI with kidney function 
decline was not statistically significant except reduction in e GFR .In our study, 
abdominal obesity was associated with renal function decline. 
  Pinto Sietsma et al 
( 19 )
,Knight EL et al 
( 72 ) 
,Mulyadi et al 
(  73 ) 
,in their study they 
suggested that microalbuminuria was associated with abnormal kidney function in 
non-diabetic individuals.  
     Some studies 
( 74 – 76 )
 suggested that there was no or inverse amount of BMI with e 
GFR decline. 
Kitiyakara et al 
( 76 )
in their study they observed WC was not associated with risk of 
CKD incidence. 
Krammer et al 
( 63 ) 
found incidence of CKD was higher in hypertensive patients with 
obesity than in hypertensive patients with normal weight. 
 
Limitations of our study: 
 Use of single measurement of creatinine 
 Need of large sample size 
 Absence of gold standard for body fat assessment ( VFA ) 
 Need to follow for years to know further renal function decline due to the effect 
of central obesity.In our study both obesity and hypertension co-existed, so it is 
difficult to establish significance of these two in the development of kidney 
damage. 
                                             
 
 
                                      CONCLUSION 
This case -control study was conducted between forty controls and forty patients with 
stage I-II chronic hypertensive kidney disease. 
                    In our study, we found that abdominal obesity was statistically 
significantly correlated with renal function decline than increase in the BMI.  
                   Abdominal obesity can be easily measured by simple methods like waist 
circumference, hip circumference and waist hip ratio with easily available instrument 
such as inch-tape . 
                  The physicians can advice the obese patients to reduce the weight and 
suggest the patients that weight reduction can reduce the incidence of hypertension 
and their complications. 
                  This study suggests, the importance of controlling the obesity, especially in 
hypertensive chronic kidney disease with initial stages of CKD and consequetively 
preventing the CKD progression. 
                 We also suggests more specific measurement of central obesity like VFA 
(Visceral Fat Area)  is needed for accurate correlation of central obesity with renal 
function decline. This study needs to be continued for years to assess the association 
of central obesity with faster renal decline. 
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ABBREVIATIONS 
 WC –Waist circumference 
BMI – Body mass index 
Wt. –Weight 
Ht.-Height 
WHR –Waist Hip Ratio 
SBP – Systolic blood pressure 
DBP – Diastolic blood pressure 
ESRD – End stage renal disease 
NIH – National Institution of Health 
ACR – Albumin creatinine ratio 
HT-CKD – Hypertensive chronic kidney disease 
GFR – Glomerular filtrate rate 
TG – Triglycerides 
VLDL – Very low density lipoprotein 
FFA –Free fatty acid 
HSL – Hormone sensitive lipase  
WHO – World health organization 
CART – Cocaine-and amphetamine-regulated transcript 
POMC – Pro-opiomelanocortin  
MCH – Melanin concentrating hormone 
 T2DM – Type II diabetes mellitus 
NKF-KD – National kidney foundation –kidney damage 
MDRD –Modification of diet in renal disease 
SNS – Sympathetic nervous system 
R-A-A-S – Renin angiotensin aldosterone mechanism 
VFA – Visceral Fat Area 
 
 
 
 
 
 
 
 
 
 
 
                                                   PROFORMA             
   TOPIC: Effect of Body Mass Index and Waist circumference on renal function in 
Hypertensive Chronic Kidney Disease 
                                 Study Group/Control Group 
 
Name:                                                                        Age:                  Sex: 
Address:                                                                   Occupation: 
 
H/O Present illness: changes in urine output, fatigue, weakness, swelling of 
feet and ankles 
Past history: diabetes mellitus, hypertension, cardiovascular disease, surgeries 
Personal history: smoking, alcohol, drug intake 
Family history: h/o similar illness in the family members 
Menstrual history: 
General examination: 
Height:                   Weight:                        Waist circumference: 
Anaemic/Not Anaemic 
Cyanosis/no cyanosis 
Clubbing/No clubbing 
Jaundice/No jaundice 
Pedal edema/No pedal edema 
Generalised lymphadenopathy present/absent 
Vital signs:                 PR:                        BP:                      RR: 
Examination of CVS: 
 Examination of  RS: 
Examination of Abdomen: 
Examination of CNS: 
Routine investigations:  
Blood Urea:             Serum Creatinine:           Urine Albumin:       
 Urine Sugar: 
 
                                                    RESULTS                                      
                                         
 
 
PARAMETERS 
 
 
   BMI 
(kg/m
2)
 
WAIST 
CIRCUMF-
ERENCE 
(cm)
 
BP 
(mmHg) 
ALBUMIN 
EXCRETION  
RATE(mg/min) 
BLOOD 
UREA 
(mg/dl) 
SERUM  
CREATININE 
(mg/dL)  
GFR 
(ml/min) 
 
CONTROL 
 
       
 
HYPERTENSIVE 
CHRONIC 
KIDNEY 
DISEASE 
(STAGE I – II ) 
 
       
 
 
 
 
 
 
                                             INFORMED CONSENT 
  I understand the procedure and voluntarily agree to participate in this 
study, I also understand that this study is a noninvasive procedure and the possible 
adverse effects have been explained to me in details clearly in my own language. 
 
                                                                              Signature of the Subject 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                              ஆராய்ச்சி ஒப்புதல் கடிதம் 
ஆராய்ச்சி தலைப்பு:  
உ஬ர் இ஭த்த அழுத்தம் சார்ந்த நீண்டகாய சிறுநீ஭க நநாய் உள்நரார் ஫ற்றும் 
ஆந஭ாக்கி஬஫ான நபர்கல௃க்கும் இடடந஬ உள்ர உடல் பரு஫ன் அரவு ஫ற்றும் இடுப்பு சுற்மரவு 
ஒப்பிடுதல். 
பப஬ர்:                    நததி:  
வ஬து:      ஆ஭ாய்ச்சி நசர்க்டக எண்: 
பாயினம்: 
       இந்த ஆ஭ாய்ச்சி஬ின் விவ஭ங்கல௃ம் அதன் நநாக்கமும் முழுட஫஬ாக எனக்கு பதரிவாக 
விரக்கப்பட்டது. 
 எனக்கு விரக்கப்பட்ட விஷ஬ங்கடரப் பற்மி நான் புரிந்து பகாண்டு எனது சம்஫தம் 
பதரிவித்நதன். 
 இந்த ஆ஭ாய்ச்சி஬ில் பிமரின் நிர்பந்த஫ின்மி  என் பசாந்த விருப்பத்தின் நபரில் நான் பங்கு 
பபறுகிநமன் ஫ற்றும் நான் இந்த ஆ஭ாய்ச்சி஬ியிருந்து எந்நந஭மும் பின்வாங்கயாம் என்படதம௃ம் 
அதனால் எந்த பாதிப்பும் ஏற்படாது என்படதம௃ம் நான் புரிந்துபகாண்நடன். 
 இந்த ஆ஭ாய்ச்சி஬ினால் ஏற்படும் நன்ட஫கடரம௃ம் சிய பக்க விடரவுகடரம௃ம் பற்மி 
பதரிவாக ஫ருத்துவர் மூயம் பதரிந்து பகாண்நடன். 
      நான் என்னுடட஬ சு஬நிடனவுடன் ஫ற்றும் முழுசம்஫தத்துடன் இந்த ஫ருத்துவ 
ஆ஭ாய்ச்சி஬ில் என்டன நசர்த்துக் பகாள்ர சம்஫திக்கிநமன 
ஆ஭ாய்ச்சி஬ாரர் டகப஬ாப்பம்    பங்நகற்பாரர் டகப஬ாப்பம் 
நாள்: 
இடம்: 
 
                
 
                                                                ஆராய்ச்சி தகவல் தாள் 
 தஞ்டச ஫ருத்துவக்கல்லூரி உடயி஬ங்கி஬ல் துடம஬ில் உ஬ர் இ஭த்த அழுத்தம் சார்ந்த 
நீண்டகாய சிறுநீ஭க நநாய் உள்நரார்க்கும் ஫ற்றும் ஆந஭ாக்கி஬஫ான  நபர்கல௃க்கும் உள்ர 
உடல்பரு஫ன் அரவு ஫ற்றும் இடுப்பு சுற்மரவுகடர ஒப்பிட்டு ஆய்வு ந஫ற்பகாள்ரப்படுகிமது. 
 இந்த ஒப்படீ்டு ஆய்வின் முடிவுகள் உ஬ர் இ஭த்த அழுத்தம் சார்ந்த நீண்டகாய சிறுநீ஭க 
நநாய் உள்நரார் ஫ற்றும் பிமர்க்கும் இடடந஬ உள்ர உடல்பரு஫ன் அரவு ஫ற்றும் இடுப்பு 
சுற்மரவு குமித்த நவறுபாடுகடர பவரிப்படுத்தும். 
 முடிவுகடர அல்யது கருத்துகடர பவரி஬ிடும்நபாநதா அல்யது ஆ஭ாய்ச்சி஬ின் 
நபாநதா தங்கரது பப஬ட஭ந஬ா அல்யது அடட஬ாரங்கடரந஬ா பவரி஬ிட ஫ாட்நடாம் 
என்படதம௃ம் பதரிவித்துக் பகாள்கிநமாம். 
 இந்த ஆ஭ாய்ச்சி஬ில் பங்நகற்பது தங்கல௃டட஬ விருப்பத்தின் நபரில் தான் இருக்கிமது. 
ந஫லும் நீங்கள் எந்நந஭மும் இந்த ஆ஭ாய்ச்சி஬ியிருந்து பின்வாங்கயாம் என்படதம௃ம் 
பதரிவித்துக் பகாள்கிநமாம். 
 இ஭த்த பரிநசாதடன஬ின் முடிவுகள் ஆ஭ாய்ச்சி஬ின்நபாநதா அல்யது ஆ஭ாய்ச்சி஬ின் 
முடிவின் நபாது தங்கல௃க்கு அமிவிக்கப்படும் என்படதம௃ம் பதரிவித்துக் பகாள்கிநமாம். 
ஆ஭ாய்ச்சி஬ாரர் டகப஬ாப்பம்    பங்நகற்பாரர் டகப஬ாப்பம் 
நாள்: 
இடம்: 
 
 
 
 
 
                                                                                                MASTER CHART 
 
S
. 
N
O
 
G
ro
u
p
 AGE 
(yrs) 
SBP 
(mmHg) 
DBP 
(mmHg) 
HEIGHT 
(meters) 
WEIGHT 
(Kg) 
BMI 
(Kg/m2) 
WC 
(cm) 
HC 
(cm) 
WHR 
 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
e GFR 
(ml/min/1.73m2) 
AER 
(mg/24 hrs) 
1 A 
42 140 90 1.61 58 22.4 82 96 0.85 42 1.16 62 40 
2 A 
45 146 86 1.58 56 22.4 84 98 0.85 51 0.91 81 42 
3 A 
47 148 90 1.68 54 19.1 76 82 0.93 48 0.88 83 43 
4 A 
53 150 96 1.6 56 21.9 82 88 0.93 46 0.95 75 54 
5 A 
49 140 90 1.56 57 23.5 84 90 0.93 45 0.87 84 53 
6 A 
43 146 96 1.62 54 20.8 82 94 0.87 60 0.92 81 48 
7 A 
40 140 90 1.6 58 22.7 80 96 0.83 41 0.89 85 36 
8 A 
52 140 86 1.58 58 23.3 86 102 0.84 42 0.88 82 39 
9 A 
46 140 90 1.6 52 20.3 82 96 0.85 44 0.96 76 35 
10 A 
43 140 88 1.6 56 21.9 82 96 0.85 46 0.88 85 42 
11 A 
47 140 90 1.58 54 21.6 84 98 0.86 48 1.02 70 45 
12 A 
52 142 88 1.62 58 22.1 80 92 0.87 52 0.86 84 52 
13 A 
45 140 90 1.65 58 21.3 81 91 0.89 51 0.89 83 55 
14 A 
45 146 92 1.62 59 22.5 82 88 0.93 53 1.02 71 46 
 15 A 
42 140 86 1.58 56 22.4 96 90 1.06 46 1.18 61 150 
16 A 
40 140 90 1.6 58 22.6 103 96 1.07 58 1.2 60 140 
17 A 
42 140 96 1.62 58 22.1 104 106 0.98 49 1.2 60 130 
18 A 
39 150 90 1.65 58 21.5 100 98 1.04 62 1.2 61 90 
19 A 
44 140 90 1.58 56 22.4 98 100 1.06 57 1.12 64 102 
20 A 
43 150 90 1.56 58 24.2 98 100 1.08 56 1.12 64 80 
21 A 
45 140 90 1.52 56 24.3 101 102 0.99 52 1.14 62 53 
22 A 
41 140 96 1.6 58 22.6 102 110 0.92 48 1.19 61 54 
23 A 
39 150 92 1.5 56 24.8 100 100 1.02 44 1.18 62 68 
24 A 
38 140 90 1.54 58 24.4 98 100 0.98 46 1.22 60 109 
25 A 
44 140 92 1.58 58 23.2 96 102 0.94 47 1.12 64 130 
26 A 
42 142 90 1.62 60 22.9 110 101 1.08 42 1.08 60 150 
27 A 
41 140 90 1.58 58 23.2 98 104 0.94 49 1.2 60 168 
28 A 
46 130 86 1.6 59 23 96 103 0.93 52 1.18 60 190 
29 A 
44 140 86 1.54 68 28.7 86 98 0.87 58 1.11 65 80 
30 A 
43 136 92 1.6 70 27.3 84 92 0.91 61 1.07 68 72 
31 A 
44 146 88 1.58 68 27.2 83 90 0.92 62 1.06 68 93 
  
 
 
GROUP A :  STUDY GROUP  
GROUP B :  CONTROL GROUP  
 
 
 
32 A 
42 140 88 1.64 72 26.8 86 102 0.84 46 1.09 67 78 
33 A 
39 140 90 1.62 66 25.2 84 96 0.87 51 1.08 68 58 
34 A 
44 140 90 1.62 70 26.7 88 98 0.89 52 1.08 67 46 
35 A 
41 148 90 1.52 60 26.1 85 95 0.89 55 1.19 61 92 
36 A 
46 146 86 1.6 68 26.6 86 96 0.89 56 1.02 71 101 
37 A 
47 140 90 1.58 65 26 80 90 0.88 58 1.08 66 52 
38 A 
47 140 88 1.52 59 25.6 82 94 0.87 61 1.18 60 48 
39 A 
40 140 90 1.6 73 28.5 85 97 0.87 49 1.02 73 38 
40 A 
43 140 90 1.56 64 26.3 82 96 0.85 58 1.08 67 40 
  
                                                                     MASTER CHART 
 
S
. 
N
O
 
G
ro
u
p
 AGE 
(yrs) 
SBP 
(mmHg) 
DBP 
(mmHg) 
HEIGHT 
(meters) 
WEIGHT 
(Kg) 
BMI 
(Kg/m2) 
WC 
(cm) 
HC 
(cm) 
WHR 
 
UREA 
(mg/dl) 
CREAT 
(mg/dl) 
e GFR 
(ml/min/1.73m2) 
AER 
(mg/24 hrs) 
1 B 
52 120 80 1.61 58 22.4 82 88 0.93 20 0.4 203 4.7 
2 B 
48 110 82 1.58 56 22.4 84 86 0.98 28 0.45 180 4.8 
3 B 
42 116 80 1.64 64 23.8 82 92 0.89 22 0.46 181 6 
4 
B  46 122 84 1.57 60 24.4 82 80 1.02 26 0.49 165 7.8 
5 
B 43 110 80 1.6 56 21.9 81 83 0.97 20 0.52 156 6 
6 
B 46 120 78 1.71 60 20.5 83 85 0.98 25 0.49 165 8 
7 
B 44 120 80 1.58 56 22.4 84 86 0.98 16 0.58 137 3.4 
8 
B 42 130 80 1.6 58 22.6 82 80 1.02 24 0.59 135 11 
9 
B 45 120 80 1.7 55 19 86 86 0.96 26 0.48 170 13 
10 
B 41 120 76 1.6 52 20.3 76 76 0.86 22 0.57 142 9 
11 
B 45 110 84 1.61 58 22.6 82 82 0.95 20 0.62 126 4.6 
12 
B 52 120 82 1.62 54 21.1 78 78 0.97 22 0.49 161 4.4 
13 
B 44 120 80 1.56 57 23.7 85 85 0.98 18 0.62 127 12 
 14 
B 43 130 80 1.6 58 22.6 86 86 0.95 30 0.63 125 10 
15 
B 47 120 82 1.58 52 20.8 80 80 0.93 24 0.54 147 1.9 
16 
B 42 118 84 1.62 56 21.8 86 86 0.97 26 0.72 108 3.8 
17 
B 43 116 78 1.64 58 22.1 85 85 0.94 32 0.4 217 6 
18 
B 48 120 82 1.68 60 2.3 82 82 0.89 20 0.69 110 7 
19 
B 42 120 80 1.59 56 22.2 81 81 0.9 18 0.62 128 4.1 
20 
B 52 120 80 1.64 58 21.5 86 86 0.96 16 0.42 192 4.8 
21 
B 49 110 70 1.71 58 20.07 82 82 0.93 18 0.56 139 9.8 
22 
B 42 110 80 1.6 56 21.9 81 81 0.92 22 0.68 115 5.6 
23 
B 49 100 76 1.58 58 23.3 83 83 1.01 24 0.63 122 5.5 
24 
B 52 110 80 1.64 56 20.8 80 80 0.94 26 0.72 103 16 
25 
B 45 120 82 1.68 56 19.86 78 78 0.95 18 0.66 117 2.8 
26 
B 52 110 70 1.56 57 23.5 82 82 0.95 23 0.53 147 5 
27 
B 49 100 76 1.52 54 23.4 85 85 0.96 20 0.59 131 8.2 
28 
B 48 106 76 1.6 56 21.1 80 89 0.89 18 0.64 120 14 
29 
B 47 110 74 1.58 54 21.6 82 86 0.95 20 0.59 132 7.1 
30 
B 38 120 80 1.6 58 22.7 82 88 0.93 22 0.73 108 2.5 
  
 
 
 
 
 
 
 
 
 
 
 
GROUP A :  STUDY GROUP  
GROUP B :  CONTROL GROUP  
 
 
 
 
31 
B 44 126 80 1.72 58 19.6 82 90 0.89 16 0.67 116 3.9 
32 
B 49 120 76 1.52 54 23.4 83 80 1.03 19 0.48 167 6.7 
33 
B 52 120 80 1.64 52 22.6 82 85 0.96 24 0.56 138 4.2 
34 
B 48 116 78 1.58 52 19.3 82 86 0.95 22 0.64 120 1.7 
35 
B 41 118 80 1.6 50 19.5 80 88 0.9 20 0.68 116 3.7 
36 
B 48 112 80 1.51 52 20.8 82 92 0.89 18 0.56 140 5.6 
37 
B 43 116 72 1.68 54 19.1 78 90 0.86 26 0.63 125 4.8 
38 
B 47 120 80 1.62 54 20.8 85 89 0.95 12 0.63 123 9.6 
39 
B 52 126 80 1.56 52 21.7 82 98 0.83 14 0.62 123 5.5 
40 
B 49 130 76 1.58 50 20 80 96 0.83 16 0.71 106 2.4 
 HT-CKD 
  
HT-CKD   HT-CKD   
BMI(Kg/m2) 
  
e 
GFR(ml/min/1.73m2)   
AER(mg/24 
hrs)   
GROUP-1 GROUP-2 GROUP-3 GROUP-1 GROUP-2 GROUP-3 GROUP-1 GROUP-2 GROUP-3 
A1 22.4 A15 22.4 A29 28.7 A1 62 A15 61 A29 65 A1 40 A15 150 A29 80 
A2 22.4 A16 22.6 A30 27.3 A2 81 A16 60 A30 68 A2 42 A16 140 A30 72 
A3 19.1 A17 22.1 A31 27.2 A3 83 A17 60 A31 68 A3 43 A17 130 A31 93 
A4 21.9 A18 21.5 A32 26.8 A4 75 A18 61 A32 67 A4 54 A18 90 A32 78 
A5 23.5 A19 22.4 A33 25.2 A5 84 A19 64 A33 68 A5 53 A19 102 A33 58 
A6 20.8 A20 24.2 A34 26.7 A6 81 A20 64 A34 67 A6 48 A20 80 A34 46 
A7 22.7 A21 24.3 A35 26.1 A7 85 A21 62 A35 61 A7 36 A21 53 A35 92 
A8 23.3 A22 22.6 A36 26.6 A8 82 A22 61 A36 71 A8 39 A22 54 A36 101 
A9 20.3 A23 24.8 A37 26 A9 76 A23 62 A37 66 A9 35 A23 68 A37 52 
A10 21.9 A24 24.4 A38 25.6 A10 85 A24 60 A38 60 A10 42 A24 109 A38 48 
A11 21.6 A25 23.2 A39 28.5 A11 70 A25 64 A39 73 A11 45 A25 130 A39 38 
A12 22.1 A26 22.9 A40 26.3 A12 84 A26 60 A40 67 A12 52 A26 150 A40 40 
A13 21.3 A27 23.2 
 
 A13 83 A27 60   A13 55 A27 168   
A14 22.5 A28 23 
 
 A14 71 A28 60   A14 46 A28 190   
 
 
 
 
 
 
 
  
 
HT-CKD 
  
HT-CKD   HT-CKD   
WC(cm) 
  
WHR   UREA(mg/dl)   
GROUP-1 GROUP-2 GROUP-3 GROUP-1 GROUP-2 GROUP-3 GROUP-1 GROUP-2 GROUP-3 
A1 82 A15 96 A29 86 A1 0.85 A15 1.06 A29 0.87 A1 42 A15 46 A29 58 
A2 84 A16 103 A30 84 A2 0.85 A16 1.07 A30 0.91 A2 51 A16 58 A30 61 
A3 76 A17 104 A31 83 A3 0.93 A17 0.98 A31 0.92 A3 48 A17 49 A31 62 
A4 82 A18 100 A32 86 A4 0.93 A18 1.04 A32 0.84 A4 46 A18 62 A32 46 
A5 84 A19 98 A33 84 A5 0.93 A19 1.06 A33 0.87 A5 45 A19 57 A33 51 
A6 82 A20 98 A34 88 A6 0.87 A20 1.08 A34 0.89 A6 60 A20 56 A34 52 
A7 80 A21 101 A35 85 A7 0.83 A21 0.99 A35 0.89 A7 41 A21 52 A35 55 
A8 86 A22 102 A36 86 A8 0.84 A22 0.92 A36 0.89 A8 42 A22 48 A36 56 
A9 82 A23 100 A37 80 A9 0.85 A23 1.02 A37 0.88 A9 44 A23 44 A37 58 
A10 82 A24 98 A38 82 A10 0.85 A24 0.98 A38 0.87 A10 46 A24 46 A38 61 
A11 84 A25 96 A39 85 A11 0.86 A25 0.94 A39 0.87 A11 48 A25 47 A39 49 
A12 80 A26 110 A40 82 A12 0.87 A26 1.08 A40 0.85 A12 52 A26 42 A40 58 
A13 81 A27 98 
 
 A13 0.89 A27 0.94   A13 51 A27 49   
A14 82 A28 96 
 
 A14 0.93 A28 0.93   A14 53 A28 52   
 
 
 
 
 
  
HT-CKD 
  
HT-CKD   HT-CKD   
CREAT(mg/dl) 
  
SBP(mmHg)   DBP(mmHg)   
GROUP-1 GROUP-2 GROUP-3 GROUP-1 GROUP-2 GROUP-3 GROUP-1 GROUP-2 GROUP-3 
A1 1.16 A15 1.18 A29 1.11 A1 140 A15 140 A29 140 A1 90 A15 86 A29 86 
A2 0.91 A16 1.2 A30 1.07 A2 140 A16 146 A30 136 A2 86 A16 90 A30 92 
A3 0.88 A17 1.2 A31 1.06 A3 140 A17 148 A31 146 A3 90 A17 96 A31 88 
A4 0.95 A18 1.2 A32 1.09 A4 150 A18 150 A32 140 A4 96 A18 90 A32 88 
A5 0.87 A19 1.12 A33 1.08 A5 140 A19 140 A33 140 A5 90 A19 90 A33 90 
A6 0.92 A20 1.12 A34 1.08 A6 150 A20 146 A34 140 A6 96 A20 90 A34 90 
A7 0.89 A21 1.14 A35 1.19 A7 140 A21 140 A35 148 A7 90 A21 90 A35 90 
A8 0.88 A22 1.19 A36 1.02 A8 140 A22 140 A36 146 A8 86 A22 96 A36 86 
A9 0.96 A23 1.18 A37 1.08 A9 150 A23 140 A37 140 A9 90 A23 92 A37 90 
A10 0.88 A24 1.22 A38 1.18 A10 140 A24 140 A38 140 A10 88 A24 90 A38 88 
A11 1.02 A25 1.12 A39 1.02 A11 140 A25 140 A39 140 A11 90 A25 92 A39 90 
A12 0.86 A26 1.08 A40 1.08 A12 142 A26 142 A40 140 A12 88 A26 90 A40 90 
A13 0.89 A27 1.2 
 
 A13 140 A27 140   A13 90 A27 90   
A14 1.02 A28 1.18 
 
 A14 130 A28 146   A14 92 A28 86   
 
